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1. INTRODUCTION 
1.1 Breast Cancer 
1.1.1 Breast cancer : an overview 
The world health organization (WHO) reported that breast cancer is one of the leading cause 
of death and the most common cancer type amongst women worldwide in 2012 [1]. Moreover, 
breast cancer ranks as the fifth cause of death from cancer overall (522,000 deaths), is the 
most frequent cause of cancer death in women in less developed countries (324,000 deaths, 
14.3% of total), and the second cause of cancer death in developed countries (198,000 deaths, 
15.4%) after lung cancer. A recent study reported that breast cancer is leading in the estimated 
new cancer cases, and the second most common death cause of women suffering from cancer 
in the USA [2]. Therefore, research and development in cancer detection and therapy is 
urgently required to solve those problems. 
Breast cancer occurs when breast cells start to grow uncontrollably. These cells can invade 
nearby tissues and spread throughout the body. Each type of tissue in the breast can form a 
cancer, but the cancer usually arises in the milk ducts or glands. Factors that influence the risk 
of breast cancer are the length of exposure to hormones (e.g. menstruation at an early age or 
late menopause), reproductive factors (e.g. no children and first pregnancy at an advanced 
age), dietary factors and lack of physical activity (e.g. obesity and dietary fat), radiation during 
breast development, hormone replacement therapy on chronic use, as well as congenital 
genetic factors associated with breast cancer like the presence of gene mutations [3].  
By molecular characteristics breast cancer is classified into luminal, HER-2 positive, and triple 
negative subtypes [4]. The luminal subtype expresses estrogen receptor (ER). Approximately 
70-75% of breast cancer cases express estrogen receptor alpha (ERα) [5], thus inhibiting 
estrogen signaling is an important target for breast cancer therapy. The HER-2 positive 
subtype expresses human epithelial growth factor receptor 2 (HER-2), therefore it responds 
well to anti HER-2 therapy.  Her-2 overexpression is detected in approximately 15-23% of 
breast cancers patient [6]. The triple negative subtype does not express ER, progesterone 
receptor (PR), and HER2, therefore it is the most difficult one to treat. Moreover, the triple 
negative breast cancer subtype represents approximately 15% of breast cancer cases with 
high index of heterogeneity [7].  
Breast cancer is a complex genetic disease due to the accumulation of various genetic 
abnormalities that affect gene expression [8]. The molecular mechanisms responsible for 
development of breast cancer is related to the expression of oncogenes such as c-myc, erbB2, 
and Ras [9], and mutations in the tumor suppressor gene BRCA1, BRCA2, and p53 [10]. Gene 
mutations can be caused by epigenetic changes or exposure to carcinogenic agents causing 
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DNA damage which then induces the initiation and malignant transformation of normal cells 
[9].   
Hormonal factors also play an important role in the development of breast cancer. Stimulation 
of tissue growth by the estrogen participates in the pathogenesis of breast cancer [11]. 
Estrogen has several different signaling pathways. The first pathway is a direct genomic 
pathway, which is started by binding of estrogen to ER in the cytoplasm, continued with 
translocation of the complex (estrogen-ER) into the nucleus, dimerization of the complex, and 
binding of the complex to the DNA at the estrogen response element (ERE). In a second, 
indirect genomic pathway, the dimerized complex binds to the DNA through protein-protein 
interactions with other classes of transcription factors, e.g. NFkB, and GATA1. A third, non-
genomic signaling pathway,started by binding of ER and estrogen in the cytoplasm, resulting 
in the activation of a kinase cascade. The fourth pathway is the ligand independent pathway, 
in which ER is activated via phosphorylation by their associated co-regulators including 
epidermal growth factor receptor (EGF), insulin-like growth factor receptor (IGFR) or human 
epidermal growth factor receptor 2 (Her2), thus leading to transcription of ER downstream 
targets in absence of estrogen [12]. 
The complexity of breast cancer mechanisms demand a comprehensive therapy. Surgery is 
the primary choice in breast cancer treatment. Surgery and radiotherapy can control local 
tumors in most patients, although more than 60% will die because of the disease if the tumor 
tissue spreads [13]. In the early stage of breast cancer, the disease is still localized in the 
mammary gland, and therefore local treatment is pursued through surgery or radiotherapy. In 
this case adjuvant therapy with chemotherapy or endocrine therapy is carried out in order to 
reduce the risk of re-emergence of the disease and to improve survival. The purpose of 
systemic chemotherapy in patients with advanced breast cancer and those who have had 
metastases is to maximize the control of symptoms, prevent serious complications, and 
prolong the patient's life expectancy [14]. Most of the patients will require multiple lines of 
therapy due to acquired resistance to chemotherapy [15].  
 
1.1.2 Classical chemotherapy doxorubicin 
Doxorubicin is an anthracycline antibiotic which is commonly used in breast cancer therapy 
[16]. The combination of docetaxel, doxorubicin and cyclophosphamide is administered as a 
standard adjuvant chemotherapy in patients before surgery [13]. Doxorubicin has several 
mechanisms of action on cellular level. First, doxorubicin inhibits topoisomerase II, resulting in 
inhibition of DNA replication. Doxorubicin is also able to intercalate with DNA, thus inhibiting 
DNA synthesis. Another study demonstrated that doxorubicin causes disturbance of the 
intracellular iron transport and disruption of intracellular ion balance. Excessive accumulation 
of intracellular iron catalyzes formation of free radicals semiquinone and reactive oxygen 
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species (ROS). Moreover, ROS induces damage in cellular elements, including DNA, either 
by direct action on DNA or by reaction with other cellular constituents to produce new ROS 
[17-21]. 
 
1.1.3 Tamoxifen, a selective estrogen receptor modulator 
As approximately 70-75% of breast cancer cases express estrogen receptor alpha (ERα) [5], 
inhibition of the estrogen receptor is a promising strategy in breast cancer therapy. Selective 
estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that 
function as agonists or antagonists for estrogen receptors (ERs) in a target gene and tissue 
dependent manner [22]. Tamoxifen emerged as the first SERM that is clinically applied in 
breast cancer treatment [23]. Tamoxifen is a triphenylethylene derivative that is metabolized 
by drug-metabolizing enzymes into active metabolites 4-hydroxytamoxifen (4-OHT) and 
endoxifen [24]. Tamoxifen blocks estrogen signaling in breast cancer cells, but increases 
endometrial stimulation and therefore increasing the risk of endometrial carcinoma at the same 
time [25].  
 
1.2 Chemoresistance 
Several advantages have been achieved for breast cancer treatment, including combinatorial 
treatment of chemotherapy and therapy with antibody and endocrine therapy, however 
chemoresistance is still a major obstacle in breast cancer treatment [26]. As few as 50% of 
patients may benefit from chemotherapy as a result of intrinsic or acquired chemoresistance 
[27], and 30% of women diagnosed with early breast cancer will progress or relapse with locally 
advanced or metastatic breast cancer [28]. Therefore, research on drug resistance formation 
and solutions to overcome drug resistance are urgently needed to achieve better efficacy of 
chemotherapeutic drugs.  
Cancer cells use several mechanism to overcome the drug treatment. Overexpression of 
multidrug efflux pumps such as P-glycoprotein (encoded by MDR1), MRP1 (encoded by 
ABCC1) and ABCG2 (encoded by BCRP) is considered to be important in cancer 
chemoresistance [29-31]. Cancer cells may also develop resistance towards DNA-damaging 
chemotherapeutic agents by preventing DNA damage and enhancing DNA repair mechanism 
[32-34]. Other mechanisms are via alteration of drug metabolism, de-arrangement of 
intracellular signaling pathway, and modification of apoptotic signaling or increased drug 
detoxification [35]. At the cellular level, cancer stem cells (CSCs) and the induction of epithelial 
to mesenchymal transition (EMT) are responsible factors for relapse [36-38].  
The known resistance mechanisms particularly of doxorubicin are decreasing the intracellular 
level of the drug by overexpressing efflux pumps [39] and increasing drug detoxification, by 
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upregulation of metabolism enzymes, e.g. glutathione S-transferase (GST) [40]. Doxorubicin 
resistant cells show reduced activity of topoisomerase II, a target of doxorubicin [41]. A recent 
studies showed that EMT and cancer stem cells are also factors causing doxorubicin 
resistance [42, 43].  
Breast cancer cells develop resistance to tamoxifen via loss or modification of estrogen 
receptor expression, alterations in co-regulatory proteins and the regulation of survival, 
proliferation, cell cycle, inhibition of apoptosis by Bcl-2, autophagy, altered expression of 
miRNA and EMT [44]. Cancer stem cells can also account for tamoxifen resistance [45]. 
Another mechanism of tamoxifen resistance is associated to the activation of epidermal growth 
factor receptors (EGFR, HER2, FGFR), NFkB, and IGF-1, as well as the signaling pathway 
alterations of PI3K/Akt/mTOR [46, 47].  
 
1.3 Salinomycin: A Promising Drug for Circumventing Multidrug 
Resistance 
Salinomycin, an ionophore antibiotic, was introduced in 2009 as cancer stem cells targeting 
drugs [48]. It was shown that salinomycin efficiently reduces metastasis formation due to a 
decrease in migratory capacity of cancer cells [49]. Furthermore, salinomycin can inhibit cell 
survival, growth, migration and invasion on human non-small lung cancer cells [50]. Other 
studies showed that salinomycin induces cell death in breast cancer cells [51], ovarian cancer 
cells [52], as well as in head and neck cancer cells [53]. Moreover, salinomycin inhibited cell 
growth and cell proliferation in prostate cancer cells [54] and pancreatic cancer cells [55]. 
Studies of salinomycin overcoming drug resistance have also been conducted. Fuchs et al. 
showed that salinomycin overcomes ABC transporter-mediated multidrug and apoptosis 
resistance in human cancer cells [56, 57]. Salinomycin increases doxorubicin and etoposide 
cytotoxicity by enhancing DNA damage and by downregulating p21 [58], and elevates 
apoptosis in cisplatin-resistant colorectal cancer cells by accumulating reactive oxygen species 
[59]. A combination of salinomycin and trail circumvents trail resistance in glioblastoma cells 
[60]. It was previously shown that a combination of salinomycin and trastuzumab efficiently 
targets cancer stem cells and Her-2-positive cancer cells [61]. Moreover, a study by Kim et al. 
showed that combined treatment of salinomycin and doxorubicin enhances the cytotoxicity in 
multidrug resistant MCF-7/MDR human breast cancer cells by decreasing the efflux of 
doxorubicin [39].  
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1.4 Molecular Evolution Assay 
Chemotherapy regimen in clinic is administered in sequential application of non–cross-
resistant chemotherapy for a defined number of cycles [62]. The application might be either 
single treatment or a combination of several chemotherapies. For instance, combinational 
treatment of docetaxel and cisplatin, as first-line chemotherapy in patients with metastatic 
breast cancer, is performed every 3 weeks for 6 cycles [63]. Another clinical study on breast 
cancer patients administered 3-weekly courses of epirubicin followed by four 4-weekly cycles 
of cyclophosphamide, methotrexate and 5-fluorouracil or four 3-weekly courses of paclitaxel 
followed by four 3-weekly cycles of epirubicin and vinorelbine [63].  
Many studies on cancer drug resistance use sequential drug treatment with an increase in 
concentration of the drugs [64-66]. Therefore, to mimic clinical application of sequential 
chemotherapy, Kopp et al. established an in vitro model named molecular evolution assay [67].  
In the molecular evolution assay (Fig. 1), cells were sequentially treated with the same dose 
of chemotherapy for several cycles/rounds, followed by a recovery time. The recovery step is 
important to get closer to the real situation in the clinic. Moreover, Kopp et al. demonstrated 
for the first time that the molecular evolution assay of doxorubicin on BT474 epithelial breast 
cancer cells resulted in significantly more resistant cells within three treatment rounds [67]. In 
addition, cell morphology revealed a change towards an EMT phenotype. Thus, the assay is 
suitable to identify drug resistance formation, because genetic alteration in each round of drug 
treatment could be tracked and identified.  
 
 
 
Fig. 1. Molecular evolution assay. Cells (80% of confluency) were treated with drugs for 72h. Medium was 
replaced with fresh medium after drug exposure, and cells were grown until recovery (80% of confluency). As soon  
as recovered, cells were splitted for protein and RNA analysis, as well as for  the next sequential  treatment  and  
also seeded for cell viability assay. R0 represents the untreated control cell line (parental cells), whereas R1 and 
R1+n represent cells which treated for one times and (1+n) times, respectively.  
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1.5 Bone Morphogenetic Protein Receptor II (BMPR2) in Cancer 
Regulation 
Cancer cells utilize very complex signaling pathways to control their cellular homeostasis. 
Transforming growth factor ß (TGF-ß) is one of the known signaling cascades maintaining a 
cancer phenotype. The bone morphogenetic proteins (BMPs), transforming growth factor 
(TGF)-β superfamily members, were originally identified as molecules regulating growth and 
differentiation of bone and cartilage, as well as teeth, skin and vascular formation [68-74]. Bone 
morphogenetic protein (BMP) type II receptor (BMPR2), a receptor for BMP ligands, is involved 
in the development of pulmonary arterial hypertension (PAH) and atherosclerosis [75-78]. 
Recent findings have revealed that BMPR2 also plays a role in cancer regulation. 
 
1.5.1 Bone morphogenetic protein (BMPs) and BMP receptors (BMPRs) 
Bone morphogenetic proteins (BMPs) are categorized into several groups i.e BMP2/4, 
BMP5/6/7/8, the growth and differentiation factor (GDF)5/6/7 and BMP9/10 [79] (Fig. 2). In 
order to start the signaling cascade, BMPs bind and interact with BMP receptors (BMPRs) [80]. 
The BMPRs consist of two types, type I and type II receptors. Type I includes activin receptor-
like kinase 3 (ALK3, or BMPRIA) and ALK6 (BMPRIB), as well as the ALK1 and ALK2 group 
[81]. Type II receptors consist of BMPR2, activin receptor 2A (ACVR2A), and activin receptor 
2B (ACVR2B) [73].  
 
 
Fig. 2. Relationships between BMP ligands, type II and type I receptors, and Smad proteins in signal 
transduction. Concerning the binding of BMPs to type I receptors, BMP-2/4 bind to BMPR-IA and BMPR-IB, 
whereas BMP-6/7 bind strongly to ALK-2, and weakly to BMPR-IB. BMP-9/10 bind to ALK-1 and ALK-2, and GDF-
5 preferentially binds to BMPR-IB. Adapted from Miyazono et al., 2010, J Biochem, 147(1): 35-51. © The Authors 
2009. Published by Oxford University Press. 
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1.5.2 BMPR signaling pathway 
BMP signaling is initiated by the binding of extracellular BMPs to heterodimeric BMP receptors 
(BMPRs) [82]. The type II receptor kinase is constitutively active in the absence of the ligand 
[73], but it cannot trigger BMP downstream signaling alone due to its poor affinity for BMP-
binding [79]. In order to initiate signaling, BMPR2 needs interaction and complex formation 
with one of the type I receptors ACVR1, BMPR1A and BMPR1B. The interactions between 
BMPR2 and type I receptors depend on the sort of BMP which binds to the type I receptor [74]. 
Both receptors need to form a hetero-oligomeric (heterodimeric) complex to trigger the 
signaling pathway. Once phosphorylated by the type II receptor, heterodimeric complex 
activates downstream effectors via two different pathways, the smad dependent and/or smad 
independent pathway [82].  
Activation of one of these pathways depends on the combination of oligomerization of type I 
and type II receptors (Fig. 3). The ligands can bind either to preformed type I-type II hetero-
oligomeric complexes (PFC), to induce the smad dependent pathway, or to the type I receptor 
followed by recruiting the best fitting type II receptor and formation of a BMP-induced signaling 
complex (BISC), to activate the smad independent pathway [82-84]. The smad dependent 
pathway requires a complex formation between activated smad 1/5/8 and the common partner 
(co)-Smad 4 for signaling, thus translocating to the nucleus and regulating interaction with 
other transcription factors of the target genes [79]. In the smad independent pathway, activated 
BISC will then trigger mitogen-activated protein kinases (MAPKs) e.g. p38 MAPK, ERK, and 
JNK, PI3K/AKT or small Rho-like GTPases [73, 82]. X-linked inhibitor of apoptosis protein 
(XIAP) is a bridging protein between type I receptor and TGF-ß activated binding protein (TAB 
1/2/3), an activator of MAPK TGF-ß activated tyrosine kinase 1 (TAK1) [85]. Accordingly, 
activation of TAK1 leads to activation of p38 via the smad independent pathway [83, 85, 86].  
The type I and type II receptor are located in the cell surface, forming either homodimeric or 
heterodimeric complexes even in the absence of the ligand [83, 86]. Homodimeric complexes 
are stable, while heterodimeric complexes are transient [87]. Homodimeric complexes of type 
I receptor are rearranged in the presence of type II receptors, leading to PFC formation and 
smad dependent pathway [88]. Moreover, homodimeric BMPR complexes may limit excessive 
formation of heteromeric PFC in the absence of ligand [87].  
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Fig. 3. Signaling pathway of BMPR2. BMP or the other ligands can bind either to (A) preformed type I-type II hetero-oligomeric 
complexes (PFC) to induce smad dependent pathway or to (B) the type I receptor continued with recruiting the best fitting type II 
receptor and formation of a BMP-induced signaling complex (BISC) to activate smad independent pathway. The smad dependent 
pathway requires a complex formation between activated smad 1/5/8 and common partner (co)-Smad 4 for the signaling, thus 
translocate to the nucleus and regulate interaction with other transcription factors of the target gene expression. In the smad 
independent pathway, X-linked inhibitor of apoptosis protein (XIAP) is a bridging protein between type I receptor and TGF-ß 
activated binding protein (TAB 1/2/3), an activator of MAPK TGF-ß activated tyrosine kinase 1 (TAK1), thus activation of TAK1 
leads to activation mitogen-activated protein kinases (MAPKs) smad independent pathway and activation of gene transcription. 
Adapted from Nohe et al., 2002, J Biol Chem, 277(7): 5330-5338. © by Baltimore, MD : American Society for Biochemistry and 
Molecular Biology 
 
 
 
1.5.3 Role of BMPR2 in cancer 
Cancer is also described as a disease caused by a damage of cell cycle regulation [89]. 
BMPR2 has shown either proliferative or anti-proliferative effects on cancer cells. Transient 
overexpression of dominant negative BMPR2 (DN-BMPR2) interfered with BMP2 inhibited cell 
proliferation, induced Smad1 signaling and G1 arrest on T47D breast cancer cells [90]. On the 
other hand, BMPR2 shows inhibition of cell proliferation on several cancer cells. In vivo 
xenograft of PC3M human prostate cancer cells transfected with dominant-negative BMPR2 
(BMPR2-DN) showed faster tumor growth, indicating that loss of BMPR2 resulted in increase 
of tumorigenicity [91].   
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The balance between cell growth and death is important in homeostasis [92]. Disturbances of 
this balance can cause pathological disorders such as disturbances in embryogenesis, neural 
degenerative diseases, as well as the development of cancer. BMPR2 has been shown to 
either suppress or promote apoptosis in cancer. Inhibition of BMPR2 by transfecting a negative 
truncated mutant of the BMP receptor-II (tBMPR2) into Tca8113 oral squamous carcinoma 
cells induced apoptosis [93]. BMPR2 anti-apoptotic activities were shown in liver cancer cells. 
A study by Zeng et al. demonstrated that inhibition of BMPR2 with siRNA increases apoptosis 
in HepG2 liver cancer cells [94]. 
Cancer cells have the ability to invade and spread throughout the body via blood and lymphatic 
vessels in a process called metastasis [95]. BMPR2 could either induce or inhibit metastasis 
in cancer cells. A study on mammary tumor progression in mice showed that disruption of 
BMPR2 accelerated mammary carcinoma metastasis [96]. Moreover, mice expressing 
dominant-negative (DN) BMPR2 had a fivefold increase in lung metastasis [96]. In contrary, 
immunostaining on lower lip squamous cell carcinoma (LLSCC) showed that BMPR2 is 
expressed higher in metastatic cells than non-metastatic cells [97].  
It is also known that transforming growth Factor-ß (TGF-ß) is involved in chemoresistance 
development by altering epithelial to mesenchymal transition (EMT), regulating stemness and 
increasing cancer cell survival protein [98-103]. BMPR2 is a receptor of TGF-β superfamily. 
Thus, the roles of BMPR2 in chemoresistance remain elusive.  
 
1.6 Aim of Thesis 
Important progress has been achieved for breast cancer treatment in recent years, including 
novel targeted therapies. However, classical chemotherapy is still one of the most frequently 
used in the clinics and thus, chemoresistance presents a major cause of breast cancer 
treatment failure. Complexity of cellular processes in breast cancer, results in the failure of the 
treatment due to lacking of signaling pathway knowledge. Therefore, research on drug 
resistance development and solutions to overcome drug resistance are urgently needed to 
achieve better efficacy of chemotherapeutic drugs. 
The first aim of the thesis was to explore the potential of salinomycin, initially a cancer stem 
cell targeting drug, in circumventing drug resistance. The mechanism of salinomycin sequential 
treatment evading doxorubicin resistance was to be investigated. Additionally, activity and 
mechanism of salinomycin in sensitizing tamoxifen-resistant cells were also to be explored.  
In the second part of the thesis, the aim was to explore the role of bone morphogenetic protein 
receptor II (BMPR2), a serine/threonine kinase and receptor of TGF-ß family member, in breast 
cancer chemoresistance. The potential use of BMPR2 as diagnostic marker and target for 
cancer therapy was further analyzed by several biological assay.
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2. MATERIAL AND METHODS 
2.1 Material 
2.1.1 Drugs 
Doxorubicin, salinomycin, tamoxifen and verapamil were purchased from Sigma Aldrich, 
Steinheim, Germany. 
 
2.1.2 Cell culture 
MCF-7, BT-474, MDA-MB 231, and MDA-MB 436 human breast cancer cells were purchased 
and cultured according to ATCC. MCF-7 cells were grown in DMEM medium high glucose 
(Gibco) supplemented with 20 % fetal calf serum (FCS) (Gibco) and 2 mM L-glutamine (Gibco) 
at 37°C and 5% CO2. BT-474 cells were grown in RPMI 1640 medium (Gibco) supplemented 
with 10 % fetal calf serum (FCS) and 2 mM L-glutamine (Gibco) at 37°C and 5% CO2. MDA-
MB 231, and MDA-MB 436 cells were grown in L-15 Leibovitz’s medium (Biochrom) 
supplemented with 10% FCS and 2mM glutamine at 37°C without CO2. For estradiol 
stimulation experiment, MCF-7 cells were cultured in DMEM high glucose phenol red free 
(Gibco) supplemented with 20% charcoal stripped fetal bovine serum (Sigma-Aldrich) and 2 
mM L-glutamine (Gibco). Cells were routinely tested and confirmed as mycoplasma free. 
 
2.1.3 Oligonucleotides 
pCPG-hCMVSCEP-BMPRII, encoded BMPR2 were purchased from imaGenes (Germany), 
Plasmid pEGFP-N1 (Clontech Laboratories, Germany) or pTRIPZ (Thermo Scientific, 
Germany) were used as a scramble control. siRNA targeting BMPR2 (ON-TARGETplus 
SMARTpool Human BMPR2: 5’-3’), and siRNA-OFF-TARGET-siScramble were purchased 
from Thermo Scientific Dharmacon® (Germany). 3x-ERE-TATA-luc plasmid (#11354), EGFR-
GFP plasmid (#32751) and HER2-GFP plasmid (#39321) were purchased from Addgene 
(Germany). 
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2.1.4 Primers 
gene UPL sequence 
ACVR2A 43 left primer    : AAAGCCCAGTTGCTTAACGA 
right primer  : TGCCATGACTGTTTGTCCTG 
ACVR2B 45 left primer    : TGTCAAGATCTTCCCACTCCA 
right primer  : AGC AGGTTCTCGTGCTTCAT 
BMPR2 5 left primer    : CAGAGGCCTAATTCTCTGGATCT 
right primer  : TCCTGATTTGCCATCTTGTG 
BMPR1A 25 left primer    :CTGTTTGGAGAAAATCAGAAGTACAG 
right primer  : CTTCAACTCCCACTGCTTTCTT 
BRCA1 8 left primer    : GTACTTCTGCCTTTAAGCCACTTC 
right primer  : CTCCAAATGTATCACTTTGTGC 
MDR1 7 left primer    : CAAGCATCTGCCAAAACCTC 
right primer  : CTGGGTTTCCCCCTGTAAAT 
BCRP1 56 left primer    : TGGCTTAGACTCAAGCACAGC 
right primer  : TCGTCCCTGCTTAGACATCC 
SOX2 35 left primer    : TTGCTGCCTCTTTAAGACTAGGA 
right primer  : CTGGGGCTCAAACTTCTCTC 
Oct4 35 left primer    : AGCAAAACCCGGAGGAGT 
right primer  : CCACATCGGCCTGTGTATATC 
Nanog 69 left primer   : ATGCCTCACACGGAGACTGT 
right primer : AGGGCTGTCCTGAATAAGCA 
E-cadherin 35 left primer   : CCCGGGACAACGTTTATTAC 
right primer : GCTGGCTCAAGTCAAAGTCC 
ERα 17 left primer  : ATCCACCTGATGGCCAAG 
right primer : GCTCCATGCCTTTGTTACTCA 
GAPDH 45 left primer   : TCCACTGGCGTCTTCACC 
right primer : GGCAGAGATGATGACCCTTTT 
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2.1.5 Antibodies 
Primary antibody 
Antigen Catalogue No Species Manufacturer 
BMPR2 6979S rabbit Cell Signalling Technology 
pSmad 1/5/8 9511S rabbit Cell Signalling Technology 
Smad 1/5/8 sc-6031-R rabbit Santa Cruz Biotechnology 
pERK 1/2 9101R Rabbit Cell Signalling Technology 
ERK 1/2 sc-93 R Rabbit Santa Cruz Biotechnology 
p21 sc-397 Rabbit Cell Signalling Technology 
pγH2AX 9718 Rabbit Cell Signalling Technology 
XIAP 2045 Rabbit Cell Signalling Technology 
Actin sc-1616-R rabbit Santa Cruz Biotechnology 
Tubulin T 9026 Mouse Sigma Aldrich 
GAPDH 14C10 Rabbit Cell Signalling Technology 
EGFR ab30 Mouse Abcam 
 
Secondary antibody 
Specification Catalogue No Species Manufacturer 
Peroxidase labeled 
anti-rabbit IgG (H+L)  
PI-1000 Rabbit Vector Laboratories 
Peroxidase labeled 
anti-mouse IgG (H+L)  
PI-2000 Rabbit Vector Laboratories 
Alexa Fluor® 488 
labelled goat anti-
rabbit IgG (H+L) 
A-11034 Rabbit  Life Technologies 
FITC labelled goat 
anti-mouse IgG (H+L) 
A-11001 Mouse Life Technologies 
 
 
2.1.6 Animals 
Female Rj:NMRI-Foxn1nu/Foxn1nu mice were purchased Janvier (Le Genest-St-Isle, France). 
The mouse strain has a mutation in the gene Foxn1 which caused thymic aplasia, resulting in 
development of immunodeficiency due to lack of thymus and hair follicle keratinization.   
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2.1.7 Kits 
Name Manufacturer 
CellTiter-Glo® Promega (Germany) 
miRCURY RNA Isolation Kit  Exiqon, Denmark 
Transcriptor High Fidelity cDNA Synthesis  Roche (Germany) 
Light Cycler 480® Probes Master Roche (Germany) 
BCA-Assay  Thermo Fisher Scientific (USA) 
OxiSelect™ Comet Assay Kit Cell Biolabs (USA) 
Caspase-Glo® 3/7 Assay System Promega (Germany) 
 
2.1.8 Instruments 
Name Manufacturer 
Phase contrast microscope Axiovert 200  Carl Zeiss (Germany) 
Fluorescence microscope Axiovert 200  Carl Zeiss (Germany) 
SP 8 SMD confocal microscope  Leica (Germany) 
TE200E spinning disc microscope Yokogawa (Japan) 
CyAnTM ADP  Dako cytomations (Germany) 
LightCycler 480 system  Roche (Germany) 
Luminometer Lumat LB960  Berthold (Germany) 
FastPrep®-24 tissue MP Biomedicals GmbH (Germany) 
Thermal cycler  Thermo Fisher Scientific (USA) 
Tecan spectra fluor plate reader  Tecan (Switzerland) 
Mini-PROTEAN® Tetra Cell Biorad (Germany) 
Thermal Cycler Thermoscientific (Germany) 
NanoDrop 2000 Thermo Scientific 
 
 
2.1.9 Software 
Name Manufacturer  
Graph Pad Prism 5 Graph Pad Software (San Diego, USA) 
FlowJo 7.6.5 FlowJo LLC (Oregon, USA) 
Infinity capture  Lumenera Corporation (Canada) 
AxioVision  Carl Zeiss (Germany) 
Image J  NIH (USA) 
CellProfiler Broad Institute (USA) 
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2.2 Methods 
2.2.1 General 
2.2.1.1 Molecular evolution assay 
Cells (80% confluency) were treated with drugs for 72 hours, as previously described [67]. 
Concentration of doxorubicin was 50 nM, while salinomycin were 500 nM for MCF-7 and BT-
474 cells, and 50 nM for MDA-MB 231 and MDA-MB 436 cells. Medium was changed with 
fresh medium after drug exposure, and cells were grown until recovered (80% confluency 
again). As soon as recovered, cells then were splitted for RNA and protein analysis, cytotoxicity 
assay, and for the next sequential treatment. R0 represents the untreated control cell line 
(parental cells), whereas R1, R2, R3, R4, and R5 represent cells which are treated one, two, 
three, four and five times, respectively. 
 
2.2.1.2 Cytotoxicity assay 
For cytotoxicity assay, 3x103 cells were seeded in 96 well plate (TPP) and incubated for 24 
hours under suitable incubation condition. Cells were then treated with drugs for 72h, continued 
with Cell Titer-Glo® assay (Promega) as manufacturer’s instruction.  
 
2.2.1.3 RNA extraction and quantitative RT-PCR 
Total RNA was extracted and isolated from cells or tissues using miRCURYTMRNA Isolation 
Kit (Exiqon, Denmark). RNA was then reverse transcribed to cDNA from 1.0 µg of total RNA 
by using Transcriptor First Strand cDNA Synthesis Kit (Roche). Real time-PCR were then 
performed in Light Cycler®480 (Roche) using Master Probes Kit (Roche) and universal probe 
library (UPL) (Roche). All protocols were performed according to instruction from 
manufacturer. RT-PCR were performed using the following primers and UPLs. GAPDH was 
used as internal control. The results were analyzed using comparative threshold cycle (∆CT 
method). 
 
2.2.1.4 Protein extraction and western blotting 
Protein was extracted from cells or tissues using lysis buffer containing Cell lysis solution® 
(Promega), protease inhibitor cocktail (Roche), and phosphatase inhibitor (New England 
Biolabs). Briefly, cells were washed three times with cold PBS, added with lysis buffer followed 
by 5 minutes incubation on ice, and harvested using cell scrapper. Supernatants were collected 
after cold centrifugation, and sample were then stored in -80oC until protein quantification. 
Protein were quantified using BCA Protein Assay Kit (Thermo Fisher Scientific). Equal 
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amounts of protein were resolved by SDS-PAGE (Bio-Rad), transferred into PVDF membrane 
(Bio-Rad) using Mini-PROTEAN® Tetra Cell (Bio-Rad), blocked with NET-gelatin for 1h, 
incubated with specific primary antibodies overnight at 4oC, and followed by 1h incubation of 
conjugated-peroxidase secondary antibody at room temperature. Antibody binding was then 
visualized using Lumi-LightPLUS western blotting substrate (Roche). Film was developed in CP 
1000 Film processor (AGFA). Quantification of western blot results were performed using 
ImageJ software.  
 
2.2.1.5 Clonogenic survival assay 
To perform clonogenic assay, 500 cells were seeded in 6-well-plate (TPP, Switzerland) and 
incubated under suitable condition for 24h prior to 72h treatment with various concentration of 
drugs treatment.Cells were then grown for 14 days, fixed and stained with para form aldehyde 
(PFA) containing crystal violet. Surviving colonies were analyzed by ColonyArea, as previously 
described [104]. 
 
2.2.2 Salinomycin circumvents drug resistance of breast cancer cells 
2.2.2.1 Internalization of doxorubicin 
Cells were treated with 10 µM of doxorubicin for 3h. Medium was changed with fresh medium 
1h prior to image and FACS analysis. Intracellular doxorubicin level was analyzed with 
fluorescence microscope Axiovert 200 (Carl Zeiss, Germany). To performed FACS analysis, 
cells were prepared by trypsinization, followed by measurement on CyAnTM ADP flow 
cytometer (DakoCytomation). Doxorubicin intracellular level were analyzed using FlowJo 
(FlowJo, LLC). 
 
2.2.2.2 Generation of tamoxifen-resistant cells 
MCF-7 tamoxifen-resistant cells (MCF-7 TAM-R6) were provided by Ann-Katrin Sommer (PhD 
student, Max Planck Institute of Biochemistry, Martinsried, Germany). MCF-7 TAM-R6 cells 
were generated by sequential treatment of 10 µM tamoxifen in 6 sequential rounds, as 
previously described [67].  
 
2.2.2.3 Transfection 
Plasmid transfection was performed either using K2® transfection system (Biontex 
Laboratories, Germany), or X-tremeGENE 9 DNA Transfection Reagent (Roche), as instructed 
by manufacturer.  
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2.2.2.4 Estrogen response element luciferase reporter assay 
Cells were transfected with 3x-ERE-TATA-Luc plasmid (#11354) (Add gene) using K2® 
Transfection System (Biontex Laboratories GmbH), as instructed by manufacturer. At 36h after 
transfection, starvation with serum free medium was performed for 12h, followed by 12h 
treatment with 1 nM 17 ß-estradiol. Cells were then treated with 100 µL cell lysis buffer (25 
mM Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton X-100). Luciferase activity 
in the cell lysate was measured using a luciferase assay kit (100 µL Luciferase Assay buffer, 
Promega, Germany) and a Lumat LB960 luminometer (Berthold, Bad Wildbad, Germany).  
 
2.2.2.5 Inhibition of EGFR recycling 
Cells were seeded in 6-well plate, and incubated for 24h prior to stimulation with recombinant 
murine epidermal growth factor (mEGF) (Pepro Tech EC Ltd., UK) and treatment with 
salinomycin. Cells were collected with trypsinization, washed with PBS, resuspended in 0.1 % 
BSA and incubated with mouse anti-huEGFR antibody (Dako, Germany) for 1h at 4 °C. After 
washing with 0.1 % BSA, samples were stained with goat anti-mouse IgG1 antibody linked to 
FITC (Molecular Probes) for 1h at 4 °C. Samples were then transferred into flow cytometry 
tube and measured on CyAnTM ADP flow cytometer (DakoCytomation).  
 
2.2.2.6 Spinning disk confocal microscopy 
Imaging experiment was performed by Dr. Frauke Mickler (Postdoctoral fellow, Dept. of 
Physical Chemistry, LMU Munich). For all imaging experiments cells were seeded in 8 well 
chambered µ-Slides (ibiTreat, Ibidi GmbH) at a density of 7000 (3 days before imaging) or 
10000 (2 days before imaging) cells per well. 
To analyze EGFR and HER-2 trafficking, 24h after seeding, cells were transfected either with 
EGFR-GFP or HER2-GFP plasmid (Addgene) using the X-tremeGENE 9 DNA Transfection 
Reagent (Roche). Receptor GFP expressing cells were imaged 48-72h after transfection. To 
detect the effect of salinomycin on receptor trafficking, salinomycin was added at concentration 
of 6 µM 3h and 24h before imaging. For co-localization with lysosomes, 15 nM lysotracker 
deep red was added into the cells, followed by 1h incubation and medium change. In order to 
induce receptor endocytosis, 50 pmol/ml EGF was added to the cells 24h before measurement.  
To analyze calcium concentration and lysosome, cells were pre-treated with 6 µM salinomycin 
for 3h or 24h or kept without salinomycin treatment. 1h before imaging, 6 µM Fluo-3-AM and 
15 nM Lysotracker deep red (both Molecular Probes, Life Technologies) were added to the 
cells. For imaging, medium was exchanged by marker-free CO2 independent medium (with or 
without salinomycin).  
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Spinning disk confocal microscopy was performed on a setup based on the TE200E 
microscope and the Yokogawa spinning disk unit CSU10. Overlay images and LUT images 
were built in ImageJ. For co-localization analysis, the ImageJ macro JaCOP was applied. 
According to a manual threshold, the fluorescence signal in the red and green was selected. 
The fraction of green pixels overlapping red pixels was calculated. Results were shown as 
Manders coefficient, M1. Mean values of all evaluated cells (N=7-13 images) were presented 
together with the standard deviation. 
 
2.2.3 BMPR2 promotes doxorubicin resistance 
2.2.3.1 Transfection 
Transfection was performed using Lipofectamine® 2000 (Invitrogen) for plasmid and 
Metafectene (Biontex) for siRNA, as instructed by manufacturers. 
Cells were seeded for the intended use : in 6-well plates (for western blot), in 12 well-plate (for 
cell cycle analysis), in 48-well plates (for cell proliferation assay), and in 96-well plates (for 
cytotoxicity and caspase activity assay).  
For the signalling experiment (western blot), 72h or 96h after transfection with plasmid or 
siBMPR2, respectively, cells were starved for 24h with serum free medium, continued with 30 
min stimulation with 20 ng/mL BMP2 (Invitogen) and lysate preparation.  
 
2.2.3.2 Cell proliferation assay 
Cells were seeded in a 48-well-plate, and incubated under suitable condition. After 24h 
incubation, cells were transfected either with plasmid or siBMPR2, and controls as previously 
described. Starting from day one after transfection, cells were harvested by trypsinization, and 
counted using Bio-rad cell counter (Bio-Rad), as manufacturer’s instruction. 
 
2.2.3.3 Cell cycle analysis 
Cells were seeded, transfected, and treated with doxorubicin as previously described. All 
floating cells were collected together with trypsinized cells, and incubated for 4h on ice in 
propidium iodide (Sigma) staining solution containing sodium citrate (Sigma) and triton X 
(Sigma), with intermittent shaking. Cells were then resuspended in PBS, transferred into a flow 
cytometry tube and measured on CyAnTM ADP flow cytometer (DakoCytomation). Cell cycle 
were analyzed using FlowJo (FlowJo, LLC).  
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2.2.3.4 Comet assay 
DNA damage was measured by the single cell electrophoresis comet assay under alkaline 
condition (OxiSelect™ Comet Assay Kit (3-Well Slides) (CellBiolabs, San Diego) as 
manufacturer’s instruction. The results were analysed by OpenComet, as previously described 
[105]. DNA damage was expressed as tail moment.  
 
2.2.3.5 Immunostaining 
Cells were grown in 8 well chambered µ-Slides (ibiTreat, IbidiGmbH) and transfected as 
previously described. After 24h treatment with doxorubicin, cells were fixed with 4% 
paraformaldehyde for 15 min, followed by permeabilization with 0.2% Triton-X 100 in PBS, 
blocking with 10% FCS + 1% gelatin + 0.05 % Triton-X 100 in PBS for 1h in room temperature, 
first antibody incubation with phospho-Histone γH2AX (Ser139) (20E3) (#9718, Cell signaling) 
overnight at 4oC, washing with PBS, and incubation with secondary antibody labeled with Alexa 
Fluor 488 (Invitrogen). Cells were counterstained with DAPI for 10 min. Images were obtained 
using a Leica SP 8 SMD confocal microscope (Germany) and image analysis was performed 
with the LAS AF software. Double strand break DNA damage was shown as number of speckle 
in the nucleus. Quantification of speckles was performed by CellProfiler, as previously 
described [106]. Immunostaining was performed together with Dr. Jonathan Garcia-Roman 
(Postdoctoral fellow, Pharmaceutical Biotechnology, LMU Munich). 
 
2.2.3.6 Caspase-3/7 activity assay 
To perform caspase assay, 5x103 transfected cells and respective controls were seeded in 96 
well plate (TPP) and incubated for 24h under suitable incubation condition. Cells were then 
treated with doxorubicin for 12h. The activity of caspase-3 and -7 was measured using 
Caspase-Glo® 3/7 Assay (Promega) as manufacturer’s instruction.  
 
2.2.3.7 Animal experiments 
MDA-MB 231 cells (5x106) were mixed with matrigel (BD Bioscience) 1:1 and inoculated 
subcutaneously into the left flank of 6 weeks old female Rj:NMRI-nu (nu/nu) (Janvier, Le 
Genest-St-Isle, France). Experiments were started 30 days after tumor cell injection. Mice were 
treated with 5 mg/kg of doxorubicin (Sigma-Aldrich) weekly for 4 weeks intravenously. Tumors 
were homogenized in a tissue and cell homogenizer (FastPrep®-24, MP Biomedicals, USA) 
using cell culture lysis buffer (Promega) or miRCURYTMRNA Isolation Kit (Exiqon, Denmark). 
Samples were then centrifuged at 14.000 rcf at 4 °C for 10 min to separate insoluble cell 
components. Protein and RNA samples were analyzed as previously described. The animal 
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experiments were performed by Johanna Busse (Veterinary MD student, LMU Munich) and 
Dr. Annika Herrmann (Pharmaceutical Biotechnology, LMU Munich). All animal procedures 
were approved and controlled by animal experiments ethical committee of Regierung von 
Oberbayern, District Government of Upper Bavaria, Germany, and carried out according to the 
guidelines of the German law of protection of animal life. 
 
2.2.4 Statistical analysis 
All data were analyzed using Prism 5.0 Software GraphPad. Statistical analysis was conducted 
using Student’s t-test. * or ** or *** or **** indicates p<0.05 or p<0.01 or p<0.001p<0.0001, 
respectively. 
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3. RESULTS 
3.1 Salinomycin Circumvents Drug Resistance of Breast Cancer 
Cells 
3.1.1 Sequential salinomycin pretreatment increases doxorubicin chemosensitivity of 
breast tumor cells 
The discovery of salinomycin as anti-cancer stem cell drug provides progress in overcoming 
chemoresistance. Question arises whether treatment of salinomycin could also circumvent 
drug resistance by its sequential treatment.  
 
3.1.1.1 Molecular evolution assay of salinomycin results in salinomycin-resistant cells 
To mimic clinical application of chemotherapeutics in vitro, sequential treatment of salinomycin 
was performed in the epithelial breast cancer cell lines MCF-7 and BT-474, as well as in the 
mesenchymal breast cancer cell lines MDA-MB 231 and MDA-MB 436. Sequential treatment 
of salinomycin results in enhanced formation of salinomycin-resistant cells. The IC50 of 
salinomycin increased during the treatment cycles, both in epithelial MCF-7 (Fig. 4A) and BT-
474 cells (Fig. 4B) as well as in mesenchymal MDA-MB 231 (Fig. 4C) and MDA-MB 436 (Fig. 
4D) cells. Furthermore, the resistant cells also displayed slightly decreased proliferation 
compared to parental cells indicated by a longer time span to reach 80% confluence (Fig. 4A-
D, middle-right panel). However, unlike in several molecular evolution assays of doxorubicin 
(Fig. S1, supplementary information), the growth retardation here is only modest.  
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Fig. 4. Molecular evolution assay reveals salinomycin-resistant cancer cells. IC50 of salinomycin during 
molecular evolution assay (left and right panel) and the day to reach an 80% confluency after cell splitting (middle 
and right panel). (A) MCF-7, (B) BT-474, (C) MDA-MB 231, (D) MDA-MB 436 cells. To determine IC50, cells were 
treated with various concentrations of salinomycin for 72h. Cell viability was measured with CellTiter-Glo assay. 
Percentage was normalized to untreated cells. IC50 was analyzed with GraphPad. R0 represents the parental cells, 
whereas R1, R2, R3, R4 and R5 represent cells that are treated for one, two, three, four and five times, respectively. 
 
 
3.1.1.2 Salinomycin resistant-cells show chemosensitivity to doxorubicin 
The final increase in resistance was compared by analyzing the cytotoxicity of 1 µM 
salinomycin of parental (R0) and salinomycin-resistant cells (R5). In MCF7, BT474 and MDA-
MB 231 an up to 3-fold increase was observed whereas MDA-MB 436 developed even higher 
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resistance (14-fold) (Fig. 5A). As salinomycin acts on other targets than classical 
chemotherapeutics, the cross-resistance to doxorubicin (5µM) was conducted by performing 
cytotoxicity assay on both resistant (R5) and parental cells (R0). The results revealed that all 
of the MCF-7, BT-474, MDA-MB 231 and MDA-MB 436 salinomycin-resistant cells (R5) 
became more sensitive to doxorubicin compared to the parental cells (R0) (Fig. 5B). When 
analyzing the IC50 for doxorubicin of R0 and R5 cells a 2- to 7-fold increase was found in 
doxorubicin sensitivity (Fig. 5C-D).  
 
 
 
 
Fig. 5. Salinomycin-resistant cells show chemosensitivity towards doxorubicin. Susceptibility of MCF-7, BT-
474, MDA-MB 231, and MDA-MB 436 R0 and R5 to (A) 1 µM of salinomycin and (B) 5 µM of doxorubicin. (C) IC50 
of doxorubicin in R0 and R5 salinomycin resistant cells. (D) Ratio of doxorubicin IC50 (R0/R5 SAL). Cancer cells of 
R0 and R5 were treated with indicated concentrations of salinomycin or doxorubicin for 72h. Cell viability was 
measured with cell titer-glo assay. Percentage was determined to untreated cells. IC50 was analyzed with 
GraphPad. Results shown as fold in comparison with R0. Results shown as fold to parental cells (R0) and represent 
the average of three independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-
test. ** or **** indicates p<0.01 or <0.0001, respectively.  
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3.1.1.3 Decreased expression of drug efflux pump genes in salinomycin-resistant cells 
A common mechanism in drug resistance is the upregulation and increased activity of efflux 
pumps, which play an important role in absorbing, distributing, and eliminating drugs from the 
cells. To determine their basal expression quantitative RT-PCR of the prominent efflux pump 
genes MDR1 and BCRP1 was performed in all parental cells (R0). MDR1 is highly expressed 
in BT-474, whereas BCRP1 is highly expressed in MDA-MB 231 cells (Fig. 6A). Furthermore, 
MCF-7 cells have the lowest efflux pumps gene expression among the analyzed cells. To 
check whether the sequential treatment of salinomycin influences the expression of drug efflux 
pumps, MDR1 and BCRP1 expression in salinomycin resistant cells (R5) was measured and 
compared to respective parental cells (R0). Both MDR1 and BCRP1 are downregulated in 
MCF-7 and BT474 resistant cells (Fig. 6B and 6E). In addition, MCF-7 salinomycin-resistant 
cells show a decrease in cancer stem cells markers SOX-2, Oct-4 and Nanog (Fig. S2, 
supplementary information). In MDA-MB 231 salinomycin-resistant cells, MDR1 is 
upregulated, and BCRP1 displayed decreased expression (Fig. 6D). MDR1 is downregulated, 
whereas BCRP1 is upregulated in BT-474 salinomycin-resistant cells (Fig. 6C). However, the 
basal BCRP1 expression in parental BT474 cells is originally very low. To sum up, a decreased 
expression of the two prominent drug efflux pumps was observed in the majority of 
salinomycin-resistant breast cancer cell lines. 
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Fig. 6. Salinomycin-resistant cells show downregulation of efflux pump. MDR1 and BCRP1 expression in (A) 
MCF-7, BT-474, MDA-MB 231 and MDA-MB 436 parental cells (R0), (B) MCF-7, (C) BT-474, (D) MDA-MB 231, (E) 
MDA-MB 436 salinomycin resistant cells (R5) compared to R0. Gene expression is determined by quantitative RT-
PCR. GAPDH was used as an internal control for quantitative RT-PCR. Results represent the average of three 
independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. * or ** or *** or 
**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. 
 
 
3.1.1.4 Blocking the efflux pumps activity affects mostly parental cells 
In order to analyze whether the decrease in efflux pump expression affects the pump activity, 
blocking of these pumps was performed with verapamil, a selective inhibitor, and cytotoxicity 
upon doxorubicin treatment was measured. In MCF-7 parental cells, addition of verapamil 
increased the doxorubicin induced cytotoxicity, whereas in salinomycin resistant cells addition 
of verapamil had almost no effect (Fig. 7A). Similar effects were also observed on BT-474 (Fig. 
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7B), MDA-MB 231 (Fig. 7C), and MDA-MB 436 (Fig. 7D). Thus, inhibition of the efflux pumps 
increases the doxorubicin-induced cytotoxicity only in parental (R0) cells.  
 
 
 
 
Fig. 7. Salinomycin-resistant cells show decreased in efflux pump activity Susceptibility of (A) MCF-7, (B) BT-
474, (C) MDA-MB 231, and (D) MDA-MB 436 R0 and R5 salinomycin to doxorubicin single treatment or in 
combination with verapamil. Cancer cells of R0 and R5 were treated with respective IC50 of doxorubicin (as shown 
in Fig. 5C), with or without 10 µM of verapamil for 72h. Cell viability was measured with CellTiter-Glo assay. 
Percentage was determined to untreated cells. Results shown as fold to parental cells (R0) and represent the 
average of three independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. 
*or **or **** indicates p<0.05 or p<0.01 or <0.0001, respectively.  
 
3.1.1.5 Salinomycin-resistant cells show increased intracellular doxorubicin 
accumulation 
As salinomycin-resistant cells show a downregulation of drug efflux pumps gene expression 
and their activity, intracellular drug accumulation was analyzed. Both the parental (R0) and 
salinomycin-resistant (R5) cells were treated with doxorubicin and the internalization of 
doxorubicin was measured by fluorescent microscopy (Fig. 8A), and FACS. An enhanced 
accumulation of doxorubicin was observed in MCF-7, BT-474, MDA-MB 436 salinomycin-
resistant cells  compared to parental cells (R0)(Fig. 8A, 8B and 8D). MDA-MB 231 salinomycin-
resistant cells (Fig. 8C) showed no change in accumulation of doxorubicin compared to 
parental cells (R0), which is in line with the enhanced MDR1 expression and reduction in 
BCRP1.  
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Fig. 8. Salinomycin-resistant cells show increased intracellular doxorubicin accumulation. Image analysis 
of intracellular doxorubicin (left panel) and FACS analysis in (A) MCF-7, (B) BT-474,  (C) MDA-MB 231, and (D) 
MDA-MB 436 R0 and R5 salinomycin. Cells were treated with 10 µM of doxorubicin for 3h. Doxorubicin was 
removed from the medium 1h prior to image analysis and FACS. For flowcytometry, cells were collected with 
trypsinization, diluted in PBS and analyzed by FACS. Results are shown as relative of mean fluorescent to 
respective untreated controls and represent the average of three independent experiments (mean ± SD). Statistical 
analysis were conducted using Student’s t-test. *** or **** indicates p<0.001 or <0.0001, respectively. 
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3.1.2 Salinomycin overcomes tamoxifen resistance of breast cancer cells 
Breast cancer cells develop resistance to tamoxifen via several mechanism e.g. loss or 
modification of estrogen receptor expression, inhibition of apoptosis and activation of ligand 
independent signaling pathway. In this part of the thesis, the effects of salinomycin in 
overcoming tamoxifen resistance were explored. 
 
3.1.2.1 Sequential tamoxifen treatment results in breast cancer resistant cells 
To investigate tamoxifen resistance, MCF-7 breast cancer cells were sequentially treated with 
10 µM of tamoxifen (Ann-Katrin Sommer, PhD student, MPI Munich). After 6 treatment cycles 
the sensitivity to tamoxifen was analyzed. In MCF-7 R6-TAM cells the IC50 value was 
significantly increased 2.8-fold (54 µM) compared to parental cells (R0), representing acquired 
tamoxifen resistance (Fig. 9A-B). A decrease in mRNA level of estrogen receptor alpha (ERα) 
was also detected in tamoxifen-resistant cells (R6) (Fig. 9C). As tamoxifen binds to ERα, one 
reason for resistance to endocrine therapy is therefore the loss of its target. The 
responsiveness of the ERα pathway to the inhibition with tamoxifen was further analyzed in 
MCF-7 TAM-R6. An ERE-luc reporter assay was used to detect estrogen signaling. Here, 
MCF-7 parental cells show a higher luciferase signal than MCF-7 R6-TAM after estradiol 
stimulation (Fig. 9D), indicating that parental cells activate the signaling pathway which is 
dependent of ERα, stronger than MCF-7 R6-TAM cells which have less ERα. E-Cadherin, an 
estradiol responsive gene, was selected to monitor ERα mediated gene transcription. 
Tamoxifen inhibition of ERα signaling after estradiol stimulation results in a decrease of E-
Cadherin expression which was only detected in MCF-7 parental cells (Fig. 9E), indicating a 
decrease of the ERα signaling pathway and subsequent target gene transcription in tamoxifen-
resistant cells. An increase in efflux pump expression and the presence of cancer stem cells 
(CSCs) are known as a reason for drug resistance. Hence, expression levels MDR1 and 
BCRP1 were analyzed by quantitative RT-PCR in parental (R0) as well as in tamoxifen-
resistant cells (R6). Sequential tamoxifen treatment enhances the expression of both multiple 
drug resistance pumps causing an increased efflux of drugs (Fig. 9F). Moreover, increased 
expression of cancer stem cell markers Nanog and Oct-4 was observed in tamoxifen-resistant 
cells (Fig. 9G). 
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followed by 1nM 17-ß estradiol treatment for 12h. Luciferase activity was normalized to the activity of the respective 
untreated control (n=5). (E) E-cadherin expression in MCF-7 and MCF-7 R6-TAM. Cells were seeded, starved with 
serum free medium for 12h, and treated with 1 nM 17-ß estradiol and 10 µM of tamoxifen for 12h. Cells were lysed 
and RNA was isolated. Gene expression is determined by quantitative RT-PCR. (F) MDR1 and BCRP1, and (G) 
SOX-2, Oct-4 and Nanog expression in MCF-7 and MCF-7 R6-TAM. Gene expression is determined by quantitative 
RT-PCR. GAPDH was used as an internal control for quantitative RT-PCR. Results represent the average of three 
independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. * or ** or **** 
indicates p<0.05 or p<0.01 or <0.0001, respectively. Tamoxifen-resistant cells (MCF-7 TAM-R6) were generated 
by Ann-Katrin Sommer (PhD study, MPI Munich). 
Fig. 9. Molecular evolution assay reveals 
tamoxifen-resistant cancer cells. (A) Cell 
viability profile and (B) IC50 of tamoxifen in MCF-
7 and MCF-7 R6-TAM. To determine IC50, cells 
were treated with various concentrations of 
tamoxifen for 72h. Cell viability was measured 
with CellTiter-Glo assay. Percentage was 
determined to untreated cells. IC50 was 
analyzed with GraphPad. (C) ERα expression in 
MCF-7 and MCF-7 R6-TAM as measured by 
quantitative RT-PCR. (D) Luciferase reporter 
assay in MCF-7 and MCF-7 R6-TAM. Cells 
were transfected with 3x-ERE-TATA-Luc 
plasmid. 36h after transfection cells were 
starved with serum free medium for 12h, 
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3.1.2.2 Salinomycin overcomes tamoxifen resistance 
It was previously shown that salinomycin is a cancer stem cells targeting drug and can enhance 
doxorubicin cytotoxicity in doxorubicin-resistant cells [39, 48]. To investigate whether 
salinomycin can circumvent tamoxifen resistance, cell viability assay of salinomycin was 
performed in both parental and tamoxifen-resistant cells. The IC50 of salinomycin in parental 
cells was previously shown in figure 4A. Tamoxifen-resistant cells (R6) are four times more 
sensitive to salinomycin than its parental cells (R0) according to their IC50 values (Fig. 10A-B). 
Therefore the combination of both drugs works better in resistant cells than in parental cells 
(Fig. 10C-D). Resistance of tumor cells to a certain drug is not only reflected in short term cell 
survival, a long-term assay represents efficacy of drugs in a better way. Thus, a clonogenic 
assay was performed by incubating the cells for two weeks to recover after the 72h drug 
treatment (Fig. 10E-F). Tamoxifen-resistant cells displayed a higher number of colonies 
without any treatment indicating an increased proliferation rate. Furthermore, salinomycin 
treatment is more effective in tamoxifen-resistant cells (R6) than in parental cells. Taken 
together, combination of the drugs showed a better effect than the single treatment, even in 
the tamoxifen-resistant cell line.  
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Fig. 10. Salinomycin overcomes tamoxifen resistance. (A). Cell viability profile and (B) fold increase of 
salinomycin IC50 (R6/R0). To determine IC50, cells were treated with various concentrations of salinomycin for 72h. 
Combinational treatment of tamoxifen and salinomycin in (C) MCF-7 and (D) MCF-7 R6-TAM. Cells were treated 
with 10 µM tamoxifen, 0.5 µM salinomycin or combination of both for 72h. Cell viability was measured with CellTiter-
Glo assay. Percentage was determined to the respective untreated cells. IC50 was analyzed with GraphPad. 
Clonogenic assay of (E) MCF-7 and (F) MCF-7 R6-TAM cells. Cells were treated with indicated concentration of 
tamoxifen, salinomycin and combination of both for 72h. The cells were subsequently cultivated for 2 weeks, and 
surviving clones were stained by crystal violet and analyzed by ColonyArea, Image J (right panel). Results represent 
the average of three independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-
test. * or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. Generation of tamoxifen-
resistant cells (MCF-7 TAM-R6) and combinational treatment of tamoxifen and salinomycin in MCF-7 cells were 
performed by Ann-Katrin Sommer (PhD study, MPI Munich).  
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3.1.2.3 Salinomycin hampers the receptor tyrosine kinases (RTKs) recycling 
One mechanism of tamoxifen resistance is associated with the activation of epidermal growth 
factor receptor (EGFR) family members [46, 47]. Therefore, to elucidate the mechanism of 
salinomycin interfering with the ligand independent activation of ERα via EGFR family 
members, the cellular distribution of EGFR and Her2 during salinomycin treatment was 
analyzed by spinning disk microscopy. To monitor the cellular fate of the RTKs, EGFR and 
Her2 with a GFP-tag were transfected into MCF-7 cells. A strong co-localization of these RTKs 
with the lysosomal marker lysotracker was detected suggesting an enhanced lysosomal 
degradation after 24h of salinomycin treatment (Fig.11A). When cells were stimulated with 
EGF the receptor disappeared from the membrane and co-localized with lysosomes. In 
contrast, single treatment of salinomycin in addition to lysosomal co-localization still displayed 
a cell surface staining indicating a balance between lysosomal degradation and de novo 
synthesis of these RTKs (Fig. 11B).  
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Fig. 11. Salinomycin induces accumulation of EGFR and Her2 in the lysosomes (A) without EGF stimulation, 
(B) with EGF stimulation. Cells were seeded in 8-well chambered µ-slides, incubated for 24h and transfected with 
EGFR eGFP or HER2 eGFP. 72h after transfection, 6 µM of salinomycin was added into the cells 3h and 24h before 
imaging. For co-localization with lysosomes, 15 nM lysotracker deep red was added into the cells, followed by 1h 
incubation and medium change. In order to induce receptor endocytosis, 50 pmol/ml EGF was added to the cells 
24h before measurement. Image was acquired with spinning disk confocal microscopy. For imaging, medium was 
exchanged by marker-free CO2 independent medium (with or without salinomycin).  Analysis of image was 
performed according to a manual threshold, by selecting the fluorescence signal in the red and green. The fraction 
of green pixels overlapping red pixels was calculated. Results were shown as Manders coefficient, M1. Mean values 
of all evaluated cells (N=7-13 images) were presented together with the standard deviation. Statistical analysis was 
conducted using Student’s t-test. * or ***or**** indicates p<0.05 or p<0.001 or <0.0001, respectively. Performed by 
Dr. Frauke Mickler (Dept. of Physical Chemistry, LMU Munich). 
 
 
As RTKs are usually recycled and return to the cell surface upon ligand stimulation and 
internalization, EGFR level at the cell surface upon salinomycin treatment was analyzed by 
FACS. Stimulation with EGF induces internalization of the surface-EGFR followed by a 
transport back to the cell surface. Salinomycin hampers the recycling process and thus 
decreases the amount of active EGFR on the cell membrane (Fig. 12A). The effect of 
salinomycin treatment on the cytosolic calcium level was also investigated. This study showed 
that the intracellular calcium level is significantly increased upon salinomycin treatment (Fig. 
12B). To sum up, salinomycin overcomes tamoxifen resistance by inhibiting of RTKs recycling.  
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Fig. 12. Salinomycin hampers EGFR recycling and increase cytosolic calcium level.  (A) Cell surface 
localization of EGFR  is hampered by salinomycin. Cells were seeded in 6-well plate, incubated for 24 hours prior 
to stimulation with recombinant murine epidermal growth factor and treatment with 6 µM of salinomycin (Sigma, 
Germany). Cells were collected with trypsinization, incubated with mouse anti-huEGFR antibody and goat anti-
mouse IgG1 antibody linked to FITC. Cells were then analyzed by CyAnTM ADP flow cytometer (DakoCytomation). 
(B) Ca2+ levels and intensity of lysosomes are elevated upon salinomycin treatment. To analyze calcium 
concentration and lysosome, cells were pre-treated with 6 µM salinomycin for 3h or 24h or kept without salinomycin 
treatment. 1h before imaging, 6 µM Fluo-3-AM and 15 nM Lysotracker deep red were added to the cells. For 
imaging, medium was exchanged by marker-free CO2 independent medium (with or without salinomycin).  Analysis 
of image was performed according to a manual threshold, by selecting the fluorescence signal in the red and green. 
The fraction of green pixels overlapping red pixels was calculated. Results were shown as Manders coefficient, M1. 
Mean values of all evaluated cells (N=7-13 images) were presented together with the standard deviation. Statistical 
analysis was conducted using Student’s t-test. ** indicates p<0.01, respectively. Image analysis was performed by 
Dr. Frauke Mickler (Dept. of Physical Chemistry, LMU Munich). 
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3.2 BMPR2 Promotes Doxorubicin Resistance in Breast Cancer 
Cells 
Acquired resistance of doxorubicin is one of the major obstacle in breast cancer treatment. 
Understanding of doxorubicin chemoresistance mechanism is urgently needed to improve its 
clinical outcome. Bone morphogenetic protein receptor type II (BMPR2) is a serine/threonine 
kinase and receptor of TGF-ß family. It is known that TGF-ß is a regulator in chemoresistance 
development by inducing epithelial to mesenchymal transition (EMT). In this part of the thesis, 
the roles of BMPR2 in promoting doxorubicin resistance was analyzed by several physiological 
assays.  
 
3.2.1 Molecular evolution assay reveals increased expression of BMPR2 in 
chemoresistant cells 
A molecular evolution assay of doxorubicin was performed using MCF-7 and MDA-MB 231 
cells to mimic clinical application of doxorubicin in an in vitro model. After five sequential rounds 
of doxorubicin treatment, cytotoxicity analysis showed that both MCF-7 and MDA-MB 231 cells 
are getting more resistant to doxorubicin (Fig.13).  
 
 
 
Fig. 13. Molecular evolution assay reveals doxorubicin-resistant cells. Susceptibility of (A) MCF-7, (B) MDA-
MB 231 cells to doxorubicin. Cancer cells of R0 and R5 were treated with indicated concentrations of doxorubicin 
for 72h. Cell viability was measured with CellTiter-Glo assay. Percentage was determined to untreated cells.  
Results represent the average of three independent experiments (mean ± SD). Statistical analysis was conducted 
using Student’s t-test. * or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. 
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To identify novel players in chemoresistance, a screening of candidates as markers of 
chemoresistance, cancer stem cells and EMT (Fig. 14) was performed by quantitative RT-
PCR. BMPR2 was found as one of the interesting candidates for doxorubicin resistance, 
showing a 2.5-fold increase in gene expression. 
 
 
 
To further strengthen BMPR2 as a suitable target, the correlation between BMPR2 level and 
cancer drug resistance in an in silico analysis was investigated by an Oncomine database 
search [107-109]. As shown in figure 15A-B, doxorubicin-resistant cells showed the highest 
expression level of BMPR2 among several different analyzed cell types and tumors. 
Additionally, cancer cells also display an upregulation of BMPR2 after they were treated with 
several drugs (Fig. 15C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Gene expression of 
chemoresistance marker in MCF-7 
doxorubicin-resistant cells (R5) 
compared to the parental cells, as 
determined by quantitative RT-PCR.  
GAPDH was used as an internal control 
for quantitative RT-PCR. Results 
represent the average of three 
independent experiments (mean ± SD). 
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Fig. 15. In silico analysis of BMPR2 expression in chemoresistance studies published in the Oncomine 
database. (A) Analysis of BMPR2 expression in comparison to doxorubicin sensitivity in different cell lines. (B) A 
study by Daigeler et al. was analyzed regarding the BMPR2 expression and doxorubicin resistance in sarcomas. 
(C) Drugs that display an increased resistance when BMPR2 is upregulated. Analysis was performed with 
Oncomine.  
 
 
Next, the change of the BMPR2 expression level during the rounds of the molecular evolution 
assay was analyzed. The results revealed that BMPR2 level increase during doxorubicin 
sequential treatment of doxorubicin in both MCF-7 and MDA-MB 231 cells (Fig. 16A-B).  
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Fig. 16. BMPR2 expression during the treatment cycles of molecular evolution assay of doxorubicin in (A) 
MCF-7, (B) MDA-MB 231 cells as determined by quantitative RT-PCR (upper panel) and western blot (lower panel). 
GAPDH and Actin were used as internal control for q RT-PCR and western blot, respectively. Results represent the 
average of three independent experiments (mean ± SD).  
 
 
3.2.2 Bone morphogenetic protein receptors expression in breast cancer cells 
BMP receptors consist of two different types, type I and type II. To explore the abundance of 
both type I (Fig. 17A), and type II BMP-receptors (Fig. 17B), a panel of breast cancer cell lines, 
was analyzed by quantitative RT-PCR. BMPR2 was detected as the most abundant receptor 
among the BMPRs. BMPR2 expression level in the breast cancer cell panel was further 
analyzed by western blotting (Fig. 17C). BT-474 cells had the highest level of BMPR2, followed 
by MCF-7, MDA-MB 231 and MDA-MB 436 cells. 
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Fig. 17. Expression of BMP receptor in breast cancer cell panel. (A) Type I receptor. (B) Type II receptor. Gene expression 
level was determined by quantitative RT-PCR. (C) BMPR2 expression as determined by quantitative RT-PCR (upper panel) and 
western blot (lower panel). GAPDH and Actin were used as an internal control for quantitative RT-PCR and western blot, 
respectively. Results represent the average of three independent experiments (mean ± SD). 
 
 
3.2.3 Modulation of BMPR2 mediates doxorubicin resistance 
In vitro sequential treatment of doxorubicin decreased the sensitivity of breast cancer cells to 
doxorubicin and simultaneously increased BMPR2 expression. In order to explore the 
mechanism of BMPR2 in chemoresistance, both BMPR2 overexpression and inhibition of 
BMPR2 with siRNA were performed (Fig.18). Treatment with various concentration of 
doxorubicin was conducted 72h or 96h after transfection with BMPR2 or siBMPR2, 
respectively, and cytotoxicity was measured.  
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Fig. 18. Overexpression and inhibition of BMPR2 in several breast cancer cells. MCF-7 cells were transfected 
with (A) BMPR2, (B) siBMPR2, and controls. MDA-MB 231 cells were transfected with (C) BMPR2, (D) siBMPR2, 
and controls. 72h or 96h after transfection with BMPR2 or siBMPR2, respectively, cells were lyzed. Gene expression 
was determined by quantitative RT-PCR (left panel) and western blot (right panel).  GAPDH and Tubulin were used 
as an internal control for quantitative RT-PCR and western blot, respectively. Results represent the average of three 
independent experiments (mean ± SD).Statistical analysis was conducted using Student’s t-test.**** indicates 
p<0.0001. 
 
 
Susceptibility of the cells towards doxorubicin was analyzed by propidium iodide staining 
(FACS) and a cytotoxicity assay (CellTiter-Glo). Analysis of the subG1 population in MCF-7 
(Fig. 19A) and MDA-MB 231 (Fig. 19B) transfected cells indicated that overexpression of 
BMPR2 decreased the subG1 population, whereas knockdown of BMPR2 increased the 
subG1 population in both cells. Cytotoxicity of doxorubicin was then determined in the 
transfected cells which were stimulated with BMP2. The cytotoxicity assays revealed that 
transient overexpression of BMPR2 decreases the sensitivity of MCF-7, but not of MDA-MB 
231 cells (Fig. 19C). Furthermore, inhibition of BMPR2 with siRNA, increases sensitivity of 
MCF-7, but not MDA-MB 231 cells (Fig. 19D).  
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Fig. 19. Modulation of BMPR2 expression mediates doxorubicin resistance. subG1 population of (A) MCF-7 
and (B) MDA-MB 231 cells with an overexpression of BMPR2 (BMPR2) or with reduced BMPR2 expression 
(siBMPR2) treated with doxorubicin (MCF-7 200 nM, MDA-MB 231 400 nM) for 72h. Cells were stained with 
propidium iodide and analyzed by FACS. MCF-7 and MDA-MB 231 cells, transfected with (C) BMPR2 or (D) siRNA 
against BMPR2 and respective controls, were stimulated with 20 ng/mL of BMP2 for 30 min and treated with 0.1, 
1, and 10 µM of doxorubicin for 72h. Cell viability was measured with cell titer-glo assay. Results represent the 
average of three independent experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. 
* or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. 
 
 
 
To confirm whether BMPR2 affects cell survival upon treatment with doxorubicin in the long 
term, clonogenic survival assay was performed by growing the cells for 14 days after 
doxorubicin treatment. Surviving colonies were quantified by measuring colony area. In 
untreated cells, BMPR2 overexpression showed a decrease in colony formation, whereas 
inhibition of BMPR2 with siRNA increases colony formation (Fig. 20A-B). Colony area of 
doxorubicin treated group was normalized to the respective untreated control. As expected, in 
doxorubicin treated cells, transient overexpression of BMPR2 increased the surviving colony 
area, whereas inhibition of BMPR2 reduced the number of surviving colony area of both MCF-
7 and MDA-MB 231 cells. 
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Fig. 20. Clonogenic assay of (A) MCF-7 and (B) MDA-MB 231 cells. Cells were transfected with BMPR2, 
siBMPR2 or scramble control and treated with doxorubicin (1, 5, 10, 20, 50 nM) for 72h. The cells were subsequently 
cultivated for 14 days, and surviving colonies were stained by crystal violet and analyzed by ColonyArea, Image J 
(lower panel). Results represent the average of three independent experiments (mean ± SD). Statistical analysis 
was conducted using Student’s t-test. * or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, 
respectively. 
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3.2.4 BMPR2 regulates cell proliferation and cell cycle 
As BMPR2 modulates colony formation, a cell proliferation assay was performed to investigate 
the role of BMPR2. The cell proliferation assay of transfected cells revealed that transient 
overexpression of BMPR2 decreases cell growth of both MCF-7 and MDA-MB 231 cells (Fig. 
21A). Vice versa, inhibition of BMPR2 with siRNA increases cell proliferation of both cell lines 
(Fig.21B). The cell proliferation assay was also conducted in MDA-MB 231 parental cells (R0) 
and R5 treatment of doxorubicin. MDA-MB 231 doxorubicin-resistant cells (R5) showed a 
decrease in cell growth compared to the parental cells (R0) (Fig. 21C). Thus, the question 
arises whether inhibition of cell proliferation was induced through a cell cycle arrest. As shown 
in the cell cycle profile (Fig. 21A-B, right panel), overexpression of BMPR2 increased the 
accumulation of cells in G1 phase and reduced the number of cells in the S phase. Accordingly, 
inhibition of BMPR2 with siRNA decreased cell accumulation in G1 phase and increased cell 
number in S phase.  
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Fig. 21. Effects of BMPR2 
modulation on cell 
proliferation and cell cycle. 
MCF-7 and MDA-MB 231 cell 
proliferation (left panel) and cell 
cycle (right panel) transfected 
with (A) BMPR2 or (B) siBMPR2 
and respective controls. For cell 
proliferation, each day cell 
number was counted by Biorad 
FACS. (c). Cell proliferation cell counter. Cell proliferation profile was depicted against day of incubation. For the cell cycle profile, cells 
were stained with propidium iodide and analyzed by FACS. (C). Cell proliferation profile of MDA-MB 231 
parental cells (R0) and MDA-MB 231 doxorubicin-resistant cells (R5). Cell number was counted by Biorad 
cell counter. Results represent the average of three independent experiments (mean ± SD). Statistical 
analysis was conducted using Student’s t-test. * or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or 
<0.0001, respectively.  
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To explore the molecular mechanism of BMPR2 inducing chemoresistance, the signaling 
pathways were further analyzed. The BMPR2 signaling cascade proceeds via smad 
dependent and independent signalling pathways which regulate several cellular processes e.g. 
cell proliferation, cell cycle, and apoptosis. Activation of both smad dependent via 
phosphorylation of smad1/5/8 and independent pathways were observed in MCF-7 cells 
transfected with BMPR2 (Fig. 22A, upper panel). Expression level of p21, a G1 cell cycle 
inhibitor and also known as a target gene of the smad dependent pathway, was elevated in 
BMPR2 transfected cells. The activation of the smad independent pathway was indicated by 
the activation of ERK. Overexpression of BMPR2 in MDA-MB 231 cells (Fig. 22A, lower panel) 
also showed an activation of the smad dependent pathway, but the effect is not as strong as 
in MCF-7 cells. Stimulation with BMP2, activates both smad dependent and independent 
pathways also in control transfected cells.  
No effect in smad dependent signaling was observed in MCF-7 transfected with siBMPR2 (Fig. 
22B). Moreover, inhibition of BMPR2 activates smad independent signaling, indicated by 
increasing of activated ERK. In MDA-MB 231 cells transfected with siBMPR2 (Fig. 22B, lower 
panel), smad dependent pathway was downregulated showing a decrease of activated smad 
and p21. In addition, both smad dependent and independent pathway can be activated by 
BMP2 stimulation. To sum up, BMPR2 overexpression activates smad dependent and 
independent signaling by targeting p21 and ERK, respectively.  
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Fig. 22. Western blot analysis of BMPR2 modulation in MCF-7 and MDA-MB 231 cells. Cells were transfected 
with (A) BMPR2 or (B) siBMPR2 and respective controls, as described in material and methods. 72h or 96 after 
transfection with BMPR2 or siBMPR2, respectively, cells were starved for 24h with serum free medium, stimulated 
with 20 ng/mL of BMP2 for 30 min, and lyzed. Protein lysates were analyzed by western blot. GAPDH was used as 
an internal control. 
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3.2.5 BMPR2 enhances the DNA repair via regulation of BRCA1 
One possible mechanism of BMPR2 inducing chemoresistance is by increasing DNA repair 
mechanisms. To confirm this hypothesis, a DNA-damage assay, the single cell electrophoresis 
comet assay, was performed in both BMPR2 and siBMPR2 transfected cells. Doxorubicin was 
used to induce DNA damage, which is demonstrated by the tail moment. Overexpression of 
BMPR2 reduced DNA damage (Fig. 23A), while inhibition of BMPR2 with siRNA enhanced 
DNA damage (Fig. 23B), indicated by increasing the tail moment in both MDA-MB 231 and 
MCF-7 cells.  
In order to identify DNA damage on molecular level, a staining with pγH2AX, a double strand 
break DNA damage marker, was performed in BMPR2 and siBMPR2 transfected cells. The 
number of speckles per nuclei was quantified, representing a double strand break. Less DNA 
damage was measured when MCF-7 cells transfected with BMPR2 (Fig. 24A), whereas more 
DNA damage was observed when BMPR2 is inhibited by siRNA in both MCF-7 and MDA-MB 
231 cells (Fig. 24B).  
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Fig. 23. Single cell comet assay of (A) BMPR2 (B) siBMPR2 transfected MCF-7 and MDA-MB 231 cells and 
respective controls after treatment with 1µM of doxorubicin for 24h. At least 100 cells were analyzed by OpenComet, 
ImageJ. DNA damage was quantified by measuring tail moment (lowe panel). Results represent mean±SEM. 
Statistical analysis was conducted using Student’s t-test. * or***or **** indicates p<0.05 or p<0.001 or <0.0001, 
respectively.  
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Fig. 24. Immunostaining of pγH2AX in (A). BMPR2, (B). siBMPR2 transfected MCF-7 and MDA-MB 231 cells and 
respective controls after treatment with 1µM of doxorubicin for 24h. Cells were stained for pγH2AX and 
counterstained with DAPI. Image were acquired with Leica SP 8 microscope (Leica Microsystem, Mannheim, 
Germany). At least 100 cells were analyzed by CellProfiler. Double strand breaks DNA damage was quantified by 
calculating number of speckles per nuclei (lower panel). Results represent mean ±SEM. Statistical analysis was 
conducted using Student’s t-test. * or**** indicates p<0.05 or <0.0001, respectively. Immunostaining and analysis 
were performed by Dr. Jonathan Garcia-Roman (Pharmaceutical Biotechnology LMU). 
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Breast Cancer-1 (BRCA1), a regulator of DNA repair mechanisms, was recently shown to be 
a novel target gene of BMPR2 signaling in endothelial cells [110]. BRCA1 expression level 
was found increased during the molecular evolution assay (Fig. 25A-B). Level of BRCA1 was 
then measured in BMPR2 and siBMPR2 transfected cells. The results showed that BMPR2 
overexpression enhanced BRCA1 expression, whereas inhibition of BMPR2 with siRNA 
decreased BRCA1 expression on both MCF-7 (Fig. 25C) and MDA-MB-231 cells (Fig. 25D). 
Moreover, treatment with doxorubicin induced higher expression of BRCA1 in BMPR2 
overexpressing cells, and accordingly showed the opposite effect in siRNA BMPR2 transfected 
cells. 
 
 
 
 
Fig. 25. BRCA1 expression level, during molecular evolution assay of doxorubicin on (A) MCF-7 and (B) MDA-
MB 231 cells. BRCA1 expression level upon transfection BMPR2, siRNA against BMPR2 and control with or without 
treatment of 1µM doxorubicin for 24h on (C) MCF-7 and (D) MDA-MB 231 cells. BRCA1 expression was determined 
by quantitative RT-PCR. GAPDH was used as internal control. Results represent the average of three independent 
experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. * or ** or ***or**** indicates 
p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. 
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3.2.6 BMPR2 modulates apoptosis by upregulating XIAP 
Cancer cells modify apoptotic signaling to circumvent the effects of chemotherapy. X-linked 
inhibitor of apoptosis protein (XIAP) is a bridging protein between type I receptor and TGF-ß 
activated binding protein (TAB 1/2/3), an activator of MAPK TGF-ß activated tyrosine kinase 1 
(TAK1) [85]. Therefore, the XIAP expression in BMPR2 and siRNA against BMPR2 transfected 
cells was measured by western blot. As shown in figure 26A, an increase in XIAP expression 
was detected in MCF-7 cells transfected with BMPR2, and the expression was even higher 
after stimulation with BMP2. However, increased expression of XIAP in MDA-MB 231 is only 
detected when cells transfected with BMPR2 and stimulated with BMP2 (Fig. 26A, lower 
panel). Inhibition of BMPR2 with siRNA leads to downregulation of XIAP in both MCF-7 and 
MDA-MB 231 cells (Fig. 26B).  
 
 
 
 
Fig. 26. Western blot analysis of XIAP in MCF-7 and MDA-MB 231 cells transfected with (A) BMPR2 or (B) 
siBMPR2 and controls as described in material and methods. 72h after transfection, cells were starved for 24h with 
serum free medium, stimulated with 20 ng/mL of BMP2 for 30 min, and lyzed. Protein lysates were analyzed by 
western blot. Actin was used as an internal control. Quantification of XIAP was performed with Image J. 
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As XIAP is an inhibitor of caspases, the activity of caspase-3/7 was then measured in both 
BMPR2 and siBMPR2 transfected cells. Doxorubicin was used to induce apoptosis. Here, 
overexpression of BMPR2 in MDA-MB 231 cells decreased the caspase-3/7 activity (Fig. 27A). 
Vice versa, caspase-3/7activity increased when BMPR2 is inhibited by siRNA (Fig. 27B). This 
effect was demonstrated only in MDA-MB 231 cells, because MCF-7 cells do not express 
caspase-3. 
 
 
 
 
Fig. 27. Caspase-3/7 activity of (A) BMPR2, (B) siBMPR2 transfected MDA-MB 231 transfected cells, and controls, 
treated with 1 and 10 µM doxorubicin for 12 h. Caspase activity was determined by Caspase-Glo®-3/7 Assay. 
Caspase activity was shown as relative to untreated cells. Results represent the average of three independent 
experiments (mean ± SD). Statistical analysis was conducted using Student’s t-test. ** indicates p<0.01.  
 
 
3.2.7 In vivo sequential treatment of doxorubicin results in the BMPR2 upregulation  
In vitro sequential treatment of doxorubicin demonstrated that BMPR2 is upregulated during 
molecular evolution assay. To verify the hypothesis that sequential treatment of doxorubicin 
enhances BMPR2 expression, an in vivo study was performed in a xenograft mouse model. 
Doxorubicin was administered four times, once per week in mice bearing MDA-MB 231 cells 
subcutaneously. As expected, a significant reduction in tumor growth was detected in the 
doxorubicin treated group (Fig. 28A,B). Western blot analysis confirmed an increase of BMPR2 
(Fig. 28C), p21 (Fig. 28D), and XIAP (Fig. 28E) in doxorubicin treated mice. To sum up, 
doxorubicin treatment in vivo induces upregulation of BMPR2.  
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Fig. 28. In vivo molecular evolution assay of doxorubicin increases BMPR2 level.  
(A) Tumor growth of subcutaneous MDA-MB 231 tumors. 30 days after the tumor was injected into the flank, mice 
were treated with 5 mg/kg of doxorubicin weekly for 4 weeks intravenously.  Tumor growth was monitored using a 
caliper, and depicted as tumor volume (mm3). (B) After 60 days, tumor volumes are represented as tumor volume 
± SD. Western blot analysis of (C) BMPR2, (D) p21, and (E) XIAP in animal tumors. ß-Actin or GAPDH were used 
as internal control. Quantification was performed by ImageJ. Results represent as mean ± SD. Statistical analysis 
was conducted using Student’s t-test. ** or *** indicates p<0.01 or p<0.001, respectively. Animal experiments were 
performed by Johanna Busse and Dr. Annika Herrmann (Pharmaceutical Biotechnology, LMU). 
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4. DISCUSSION 
4.1 Cancer Drug Resistant Cells Obtained from Molecular Evolution 
Assays 
Chemoresistance is still a major threat to a successful cancer therapy. To investigate novel 
mechanisms and drugs circumventing therapy resistance, sequential treatment of salinomycin 
or doxorubicin or tamoxifen was performed in epithelial and mesenchymal breast cancer cells, 
which generated drug resistant cells. Many studies on cancer drug resistance utilize 
continuous drug treatment with increasing concentrations of the drugs [65, 66, 111, 112]. 
However, clinical study on patients with non-resectable colorectal cancer suggested that 
sequential use of the same cytotoxic drugs is more effective than combination therapy [113]. 
In the present study, breast cancer cells were treated with the same concentration of drugs, 
on the one hand with classical chemotherapeutic drug doxorubicin, and on the other hand with 
salinomycin, a novel anti cancer stem cell drug, and followed by recovery period after the 
treatment. This procedure was performed for 5-6 treatment cycles. These settings have the 
advantage to mimic the application process of chemotherapeutics in the clinics.  
 
4.2 Salinomycin Circumvents Drug Resistance of Breast Cancer 
Cells 
4.2.1 Sequential salinomycin pretreatment increases doxorubicin chemosensitivity of 
breast tumor cells by downregulating efflux pumps 
The resistance formation in the molecular evolution assay with salinomycin exhibits no linear 
increase of the IC50 for salinomycin. One could conclude that the resistance formation here is 
based on the principle of clonal selection. According to the clonal evolution theory, tumor cells 
display heterogeneity and genetic instability. When treated with chemotherapy a selection 
pressure is applied and some of the cells will survive the treatment. These cells will form a new 
polyclonal cell population with various genetic predispositions [114]. After each round of the 
molecular evolution assay, different cell population might have survived and thus no linear 
increase in the IC50 was detected in this study. Additionally, many different resistance 
mechanism possibly exist in parallel caused by the clonal selection in the molecular evolution 
assay. For example the decrease of cell proliferation indicates that salinomycin treatment 
eradicates fast growing cell populations. Unlike in several molecular evolution assays of 
doxorubicin the growth retardation here is only modest. A recent study by Kopp et al. also 
showed that sequential treatment of mesenchymal breast cancer cells with salinomycin 
resulted in resistance formation by mesenchymal to epithelial transition (MET) [115]. 
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Interestingly, salinomycin-resistant cells exhibit increased sensitivity to doxorubicin in both, 
epithelial and mesenchymal tumor cells. As it was reported that combinatorial treatment, i.e. 
simultaneous treatment, of salinomycin with doxorubicin, cisplatin or etoposide increased the 
cytotoxicity [58, 59], this study hypothesize that in the molecular evolution assay the sensitivity 
for other drugs was increased as well.  
The most important drug resistance mechanism is the upregulation and increased activity of 
ABC-transporters (ATP binding cassette transporter) [116]. Among these efflux pumps in 
charge of decreasing intracellular drug level are p-glycoprotein (encoded MDR1 gene), breast 
cancer resistance protein (encoded by BCRP1 gene), and multidrug resistance associated 
proteins (encoded by MRP genes) [65, 117-119]. The ABC transporter family consists of 
membrane proteins that translocate a variety of substrates across extra- and intracellular 
membranes [65]. They play an important role in absorbing, distributing, and eliminating drugs 
from the cells [120]. Hence, the upregulation of efflux pumps decreases intracellular drug 
accumulation and increases drug resistance so called multiple drug resistance (MDR). 
Several multiple drug resistance reversing agents modify cell membrane fluidity and increase 
cell membrane permeability [121]. Salinomycin is able to circumvent multidrug resistance by 
acting as ionophore. Salinomycin, a transmembrane K+ ionophore is embedded in biological 
membranes, and thus by changing membrane integrity it is able to inhibit the activity of drug 
efflux pumps. Additionally, salinomycin disturbs the intracellular balance of ions by increasing 
the potassium level [122, 123]. In this study, MDR1 and BCRP1 are downregulated after 
sequential salinomycin treatment. 
The decrease of the expression of multidrug resistance proteins can occur via a direct and 
indirect mechanism (Fig. 29). On the one hand, salinomycin was found to be an anti-cancer 
stem cell drug. One of the hallmarks of cancer stem cells is an increase of efflux pump activity. 
That is why cancer stem cells are thought to be present in the side population. Salinomycin is 
eradicating this population and thereby increasing the non-cancer stem cell fraction with low 
efflux pump expression. Cancer stem cells markers SOX-2, Oct-4 and Nanog were 
downregulated in MCF-7 salinomycin-resistant cells (R5-SAL), thus supporting the hypothesis 
that by cyclic drug treatment the offspring of these efflux pump-positive cancer stem cells also 
die out over time. However, whether the killing of cancer stem cells and their offspring accounts 
for such a strong effect in gene expression of efflux pumps and eventually doxorubicin 
sensitivity, remains to be elucidated. On the other hand, efflux pumps might be important for 
the direct execution of salinomycin cytotoxicity as they regulate the intracellular balance of 
molecules. 
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Fig. 29. Model of salinomycin decreased drug efflux pump. On the one hand, salinomycin is eradicating cancer 
stem cell population which overexpress efflux pumps, and therefore increasing the non-cancer stem cell fraction 
with low efflux pump expression. On the other hand, salinomycin is also embedded in biological membranes, and 
thus by changing membrane integrity it is able to inhibit the activity of drug efflux pumps.  
 
 
 
In contrast to the breast cancer cell lines MCF7 and MDA-MB 436, where MDR1 and BCRP1 
expression was decreased, an upregulation of some of these proteins in BT-474 and MDA-MB 
231 cells is observed. BCRP1 is increased 7- fold in BT-474. However, the BCRP1 level in BT-
474 parental cells is very low compared to the other cells, thus the upregulation in salinomycin-
resistant cells did not influence the efflux pump activity substantially, as shown by blocking the 
pump activity with verapamil.  
Doxorubicin is a substrate of p-glycoprotein [65], while verapamil acts as competitive inhibitor 
by specific binding to p-glycoprotein [124], thereby preventing doxorubicin efflux across the 
cell membrane. In contrast to BT474, MDA-MB 231 salinomycin resistant cells displayed a 6-
times higher increase in MDR1 which resulted in increased efflux activity. The increased 
doxorubicin sensitivity is therefore due to a different mechanism. Since ABC transporters are 
downregulated in salinomycin-resistant cells, an enhanced doxorubicin accumulation was 
observed. Doxorubicin induces DNA damage by generating malondialdehyde-DNA adducts 
induced by free radicals [19]. Hence, increased DNA damage in salinomycin resistant cells is 
hypothesized. These findings suggest salinomycin treatment of chemoresistant tumors is an 
option in order to resensitize them.  
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In conclusion, this study demonstrated that sequential salinomycin treatment generates 
salinomycin-resistant cells and increases susceptibility to doxorubicin by downregulation of 
MDR1 and BCRP1 gene expression. However, due to the complexity of the genetic changes 
based on clonal selection during the molecular evolution assay, a comprehensive study e.g. 
next generation sequencing or a proteomics approach would further increase our 
understanding of chemoresistance mechanisms and improve clinical application of 
chemotherapeutics.  
 
4.2.2 Salinomycin overcomes tamoxifen resistance of breast cancer cells by inhibiting 
RTKs recycling 
The luminal subtype is the most common breast cancer cases with an incidence of 70-75 % 
[5]. Due to its dependency on ERα signaling, inhibition of the signaling with tamoxifen and 
other SERMs is considered as a frontline treatment. However, in about 20-30% of these cases, 
tamoxifen therapy fails because of existing or acquired resistance [46]. In this study, in 
collaboration with A.-K. Sommer (PhD student, MPI, Munich), sequential treatment of 
tamoxifen was performed in MCF-7 breast cancer cells. A decrease in ERα expression, 
increase in efflux pump genes expression, cancer stem cell marker and the activation of ligand-
independent signaling were identified in tamoxifen-resistant cells.  
Loss or modification in ERα expression is one of the mechanisms related to tamoxifen 
resistance [44]. Therefore, to maintain the proliferation, tamoxifen-resistant cells activate 
alternative pathways independent from the genomic cascade, including activation of ERα by 
epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 (IGF-1) receptor [12, 
46].  Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor 
tyrosine kinases, including EGFR/ErbB1/HER1, ErbB2/HER2/Neu ErbB3/HER3, and 
ErbB4/HER4 [125]. 
The ligand independent activation of ERα by EGFR family members and other RTKs plays an 
important role in tamoxifen resistance development [126-128]. A previous study showed 
upregulation of RTKs in tamoxifen-resistant cells [129, 130]. Moreover, tumors of patients with 
acquired tamoxifen resistance showed significantly higher EGFR levels compared to sensitive 
breast cancer samples [131]. This findings, further highlight the impact of the EGFR-family in 
breast cancer.  
In tamoxifen-resistant cells upregulation of both cancer stem cells marker and ABC transporter 
efflux pumps was observed. As previously shown, salinomycin is able to eradicate cancer stem 
cells and to overcome ABC mediated drug resistance [56, 59, 132], and thereby, on the one 
hand salinomycin is able to overcome tamoxifen resistance by those mechanisms. On the 
other hand, salinomycin can also interfere with the ligand independent activation of ERα. A 
previous study by A.K. Sommer showed that salinomycin reduces the expression and 
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phosphorylation of Her2 and Her3 and thus is able to block their activation by tamoxifen 
treatment [133].  
In this present study, FACS analysis showed that EGFR as well as Her2 disappear from cell 
surface and spinning disk microscopy revealed that both accumulate in lysosomes followed by 
degradation. Boehmerle et al. discovered that increased intracellular calcium levels induced 
by salinomycin are responsible for a pre-mature fusion of endosomes with lysosomes in 
neurons [134].  In order to verify this effect in breast cancer cells, the intracellular calcium 
levels was investigated in in vitro system and determined a significant elevation upon 
salinomycin treatment. 
Combined targeting of ERα and RTKs is an effective solution to overcome tamoxifen 
resistance. Modulating ERα with SERMs i.e tamoxifen not only inhibits the genomic estrogen 
signaling pathway, but also activates the ligand independent pathway by upregulating RTKs. 
In this study, combined treatment of tamoxifen and salinomycin showed beneficial effect in 
both tamoxifen-sensitive and -resistant cells, even in the low dose. Salinomycin not only 
prevents resistance development to endocrine therapy but also eradicates already resistant 
breast cancer cells. Sommer demonstrated that combined treatment of tamoxifen and 
salinomycin reduces the expression levels of ERα as well as all EGFR- family RTKs, indicating 
inhibition of the ligand independent signaling which is turned on after single treatment of 
tamoxifen [133]. Combined treatment of tamoxifen and salinomycin is beneficial because 
tamoxifen blocks the genomic pathway, while salinomycin inhibits the ligand independent 
pathway of the estrogen signaling. This findings provide a novel treatment strategy for luminal 
subtype breast cancer patient in order to overcome tamoxifen resistance.  
 
4.3 BMPR2 Promotes Doxorubicin Resistance in Breast Cancer 
Cells 
This part of the thesis demonstrates that sequential treatment of doxorubicin induces MCF-7 
and MDA-MB 231 doxorubicin-resistant cells. To explore the mechanism of doxorubicin 
chemoresistance, screening for drug resistance marker was performed, showing BMPR2 to 
be one of the interesting candidates. Consequently, BMPR2 upregulation was observed during 
the round of molecular evolution assay.  
To investigate the role of BMPR2 in acquired doxorubicin resistance, two different cell lines, 
epithelial MCF-7 and mesenchymal MDA-MB 231 were used. Modulation of BMPR2 
expression in both cells line was performed by overexpressing BMPR2 which reduced the 
sensitivity to doxorubicin, and inhibiting BMPR2 with siRNA which enhanced susceptibility to 
doxorubicin. A reduction in cell growth was observed during the molecular evolution assay of 
doxorubicin, therefore cell proliferation and cell cycle profile were also analyzed in both MCF-
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7 and MDA-MB 231 cells upon BMPR2 or siBMPR2 transfection. Overexpression of BMPR2 
reduces cell proliferation and induces cell cycle arrest, whereas inhibition of BMPR2 increases 
cell proliferation.   
To further explore the molecular mechanism of BMPR2 inducing chemoresistance, BMPR 
signaling pathways were investigated in both BMPR2 and siBMPR2 transiently transfected 
cells. BMPR2 signalling consists of 2 different pathways i.e the smad dependent and the 
independent pathway [73]. The smad dependent signaling pathway involves phosphorylation 
of smad1/5/8, complex formation of activated smad1/5/8 with co-smad4, and translocation of 
the complex to the nucleus to modulate gene transcription [82-84]. The smad independent 
pathway utilizes MAP kinase pathway for its signaling cascade [73, 82]. 
Activation of both smad dependent and independent pathways of BMP signaling in BMPR2 
transfected MCF-7 cells was observed in this study. In MDA-MB 231 cells, overexpression of 
BMPR2 activated only the smad dependent pathway, and treatment with BMP2 stimulated 
both the smad dependent and the independent pathway. Cells develop resistance mechanism 
by modulating cell cycle and cell proliferation. It is known that p21, an inhibitor of cyclin-CDK 
in G1 phase of cell cycle is a common target of all TGF-ß superfamily pathways via the smad 
dependent mechanism [135]. A previous study by Kim et al. on bladder cancer cells showed 
that BMPR2 overexpression leads to restoration of BMP signaling and decrease in tumor 
growth [136]. In this present study, an increase in p21 upon overexpression of BMPR2 was 
observed in MCF-7 cells which have wild type p53 gene. The p53 acts as a tumour suppressor 
gene and regulates transcription of p21 [137]. p53 is also supposed to interact with smad2 and 
smad4 and therefore has a direct interlinkage to the smad dependent signalling pathway [138, 
139]. MDA-MB 231 cells have a mutant p53 gene [140], therefore intense expression of p21 
upon transfection of BMPR2 could not be observed.  
Activation of the smad independent pathway in BMPR2 transfected MCF-7 cells was observed 
by increase in activated ERK1/2. In this study, ERK activation induces cell cycle arrest rather 
than cell proliferation. In general, activated ERK can regulate the expression of cyclin D1, a 
regulator of cell cycle, and can also regulate the post translational regulation of the assembly 
of cyclin D-CDK4/6 complexes, thereby induces cell cycle progression [141]. However, a study 
by Park et al. on primary hepatocytes showed that activated ERK increases the 
phosphorylation of the transcription factors Ets2, C/EBPalpha, and C/EBPbeta, which rapidly 
enhance transcription of the p21 promoter via multiple Ets- and C/EBP-elements within the 
enhancer region, thus resulting in increase of p21 expression and induction of cell cycle arrest 
[142]. Accordingly, activation of the smad independent pathway in the present study, might 
also increase p21 and cell cycle arrest via the same or similar mechanism. However, this 
hypothesis remains to be investigated. 
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In MCF-7 cells inhibition of smad dependent pathway by siBMPR2 can be counter balanced 
by p53 inducing p21 expression, however this mechanism does not occur in MDA-MB 231 
cells which have a mutant p53 gene. Inhibition of BMPR2 in MCF-7 cells enhances ERK 
activation which stimulates cell proliferation. However, no change in ERK activation was 
observed in MDA-MB 231 transfected with siBMPR2. MDA-MB 231 cells have mutant KRAS 
gene [110], which constitutively induces Ras activating ERK and PI3K/AKT pathways [143], 
and thereby the smad independent pathway cannot be inhibited by siBMPR2. Taken together, 
BMPR2 upregulation results in p21 inducing cell cycle arrest, thus provides tumor cells with 
more time to modulate DNA repair mechanisms.  
Cancer cells may develop chemoresistance towards DNA-targeting chemotherapeutic agents 
by regulating DNA damage and DNA repair mechanisms [32-34]. A recent study on pulmonary 
arterial hypertension (PAH) by Li et al. showed that BMPR2 expression is tightly linked to DNA 
damage control, and moreover breast cancer 1 (BRCA1) was identified as a novel target of 
BMPR2 and a novel modulator of PAECs homeostasis [42]. In addition, in the presence of 
BMPR2, DNA damage can be repaired by BRCA1-related pathways, thus maintaining vascular 
homeostasis. In the present study DNA damage upon treatment with doxorubicin was 
observed in both BMPR2 and siBMPR2 transfected cells by single cell comet assay and 
measuring double strand break DNA damage marker γH2AX. The results revealed less DNA 
damage in BMPR2 transfected cells and more DNA damage in siBMPR2 transfected cells. 
Upregulation of BRCA1 was detected during the round of molecular evolution assay. 
Additionally BRCA1 upregulation upon BMPR2 overexpression was observed in MCF-7 and 
MDA-MB 231 cells, and the level of BMPR2 was induced upon doxorubicin treatment. In 
contrary, inhibition of BMPR2 with siRNA reduced BRCA1 expression. Taken together, these 
findings suggest BMPR2 upregulation leads to an increased in DNA repair mechanisms by 
upregulating BRCA1. 
Cells can also circumvent drug treatment by enhancing anti-apoptotic mechanisms. It is known 
that XIAP is a part of the BMP signaling pathway and a positive regulator, linking the BMP 
receptors withTAB1-TAK1, a member of the MAP kinase kinase kinase family [85]. XIAP 
inhibits either initiator caspase-9, or effectors caspase-3/7 in the apoptosis pathway [144]. DNA 
damage or other events that result in the induction of apoptosis can lead to ubiquitination and 
auto-ubiquitination of  XIAP [145]. A previous study by Liu et al. suggested that activation of 
BMPR2 stabilizes XIAP by preventing ubiquitination and subsequent degradation [146, 147]. 
Furthermore, inhibition of BMPR2 with siRNA induces apoptosis by destabilization XIAP, and 
induces autophagy via XIAP-mdm2-p53 pathway [148].  
This present study demonstrates that XIAP is upregulated upon BMPR2 overexpression, and 
downregulated upon inhibition by siBMPR2. The expression of XIAP is even higher upon 
stimulation with BMP2. Moreover, XIAP upregulation leads to decrease in caspase activity, 
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while XIAP downregulation enhances caspase activity. Accordingly, overexpression of BMPR2 
in doxorubicin-resistant cells enhances the anti-apoptotic mechanism by stabilizing XIAP, but 
the exact mechanism requires further studies.  
Sequential treatment of doxorubicin in a xenograft mouse model showed a significant reduction 
in tumor growth. Moreover, upregulation of BMPR2, p21 and XIAP was also observed in 
doxorubicin treated mice. In summary, this study findings show an increase in BMPR2 
expression upon sequential doxorubicin treatment both in vitro and in vivo. The mechanism of 
BMPR2 promoting chemoresistance by modulation of proliferation, cell cycle, DNA repair and 
apoptosis is depicted in Fig. 30. BMPR2 undergoes signaling via both smad dependent and 
independent pathways. The smad dependent pathway induces p21 inhibiting cell cycle and 
cell proliferation, as well as BRCA1 upregulating DNA repair. The smad independent signaling 
increases XIAP stabilization leading to inhibition of apoptosis. Taken together, these pathways 
enhance cell survival upon DNA-damaging drugs. 
 
 
 
 
Fig.30. Model of BMPR2 mediated chemoresistance. Chemotherapeutic treatment of tumor cells induces a 
selection of chemoresistant cells. These cells display an increased level of BMPR2. The BMPR2 downstream 
signaling results in two pathways which are important for the formation and prolongation of chemoresistance. On 
the one hand, cells are able to evade the toxic stress of chemotherapeutics by arresting cell cycle via p21 and 
upregulating the DNA repair enzyme BRCA1. On the other hand BMPR2 is able to induce anti apoptotic effects by 
stabilizing XIAP. The increased signaling of BMPR2 thus facilitates the repair of DNA damage and survival of tumor 
cells.  
DISCUSSION 
61 
 
Some studies on compounds or gene therapeutic approaches which modulate BMPR2 
signaling have been conducted to treat dysregulation of BMP signaling in several physiological 
processes. On the one hand, adenovirus-mediated BMPR2 gene delivery to the pulmonary 
vascular endothelial cells using in vivo models of PAH showed therapeutic potential for 
upregulation of BMPR2 [149, 150]. On the other hand, adenovirus-mediated siRNA BMPR2 
delivery in in vivo model promises a candidate for osteolysis treatment [151]. Development of 
a small molecule targeting BMP signaling has also been established. FK506 (tacrolimus) binds 
FK-binding protein-12 (FKBP12), a repressor of BMP signaling which release FKBP12 from 
type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3, and activates the smad 
dependent and smad independent signaling pathways, thus normalizing BMP signaling in PAH 
[76]. Nevertheless, targeting BMPR2 in cancer therapy remains elusive.  
This present study provides new insights into the role of BMPR2 in doxorubicin 
chemoresistance of breast cancer cells. The use of BMPR2 inhibitor may enhance efficacy of 
chemotherapeutics and overcome drug resistance. Moreover, targeted therapy on either the 
smad dependent or independent signaling pathways is also an interesting topic for future 
cancer drug development. 
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5. SUMMARY 
Important progress has been achieved for breast cancer treatment in recent years, however, 
classical chemotherapy is still one the most frequently used in clinics, and therefore 
chemoresistance is still a major challenge for successful breast cancer therapy. As a result of 
intrinsic or acquired chemoresistance, tumors will progress or relapse with locally advanced or 
metastatic breast cancer. Accordingly, research on drug resistance formation and solution to 
overcome drug resistance is urgently needed to achieve better efficacy of chemotherapeutic 
drugs. In this present study, clinical application of chemotherapy is mimicked by an in vitro 
model called molecular evolution assay. Cells were sequentially treated with the same dose of 
drugs (doxorubicin or salinomycin) for several cycles/rounds, followed by a recovery time. 
The discovery of salinomycin as anti-cancer stem cell drug provides progress in overcoming 
chemoresistance. However, a study on whether long term application of salinomycin is able to 
abolish drug resistance remained elusive. In this study, sequential treatment of salinomycin 
was performed in MCF-7 and BT-474 epithelial breast cancer cells as well as MDA-MB 231 
and MDA-MB 436 mesenchymal cells and the gene expression of multiple drug resistance 
(MDR) genes was further analyzed. Here, sequential treatment of salinomycin generated 
resistance in all cell lines and increased the chemosensitivity towards doxorubicin. Drug efflux 
pump gene expression and the pump activity of MDR1 and BCRP1 were downregulated in 
these cells. Moreover, intracellular drug accumulation was increased compared to the 
respective parental cells. These findings suggest a novel treatment option for multiple drug 
resistant tumors by sensitizing these tumors via salinomycin pretreatment.  
The luminal subtype of breast cancer is the most common breast cancer cases, and due to its 
dependency of estrogen signaling, inhibition of the signaling with tamoxifen is considered as 
the firstline treatment. However, cells develop resistance to tamoxifen by activating ligand 
independent signaling pathway. In this part of the thesis, sequential treatment of tamoxifen on 
MCF-7 cells generated tamoxifen-resistant cells. Upregulation of efflux pumps and cancer 
stem cell marker, but downregulation of ERα gene expression was observed in tamoxifen-
resistant cells. Here, salinomycin circumvents tamoxifen resistance by inhibiting ligand 
independent pathway. Therefore combinational treatment of tamoxifen and salinomycin is a 
novel strategy to improve clinical efficacy of tamoxifen.  
Doxorubicin is the most commonly used chemotherapy in clinic, and therefore exploring 
chemoresistance mechanism of doxorubicin is urgently needed to improve its clinical outcome. 
Bone morphogenetic protein receptor type II (BMPR2) is a serine/threonine kinase and 
receptor of TGF-ß family. BMPR2 can regulate bone, teeth, and vascular formation, as well as 
kidney regulation and hypertension. In this part of the thesis, BMPR2 was identified as a 
promising target of doxorubicin resistance. This study demonstrates that BMPR2 promotes 
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doxorubicin chemoresistance in breast cancer cells via regulating cell proliferation and cell 
cycle, DNA repair, and apoptosis. Furthermore, increased BMPR2 expression in doxorubicin-
resistant breast cancer cells was confirmed in a xenograft mouse model. These findings show 
a novel role of BMPR2 in breast cancer chemoresistance. Antagonizing BMPR2 action might 
improve clinical outcome of breast cancer patients by sensitizing resistant tumor cells to 
doxorubicin.  
In this thesis many options to circumvent chemoresistance were found. Further studies are 
needed to validate these novel treatment options.
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6. APPENDIX 
6.1 Supporting Information Chapter 3.1.1 
 
 
 
Fig. S1. The time to reach an 80% confluency after cells splitting during the molecular evolution assay of 
salinomycin (SAL) and doxorubicin (DXR).  (A) MCF-7, (B) BT-474, (C) MDA-MB 231, (D) MDA-MB 436 cells.  
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Fig. S2. Molecular evolution assay of salinomycin in MCF-7 cells results in downregulation of cancer stem 
cells marker gene expression. SOX-2, Oct-4 and Nanog expression in MCF-7 and MCF-7 R5-SAL were 
determined by quantitative RT-PCR. GAPDH was used as an internal control for quantitative RT-PCR. Results 
represent the average of three independent experiments (mean ± SD). Statistical analysis was conducted using 
Student’s t-test. * or ** or ***or**** indicates p<0.05 or p<0.01 or p<0.001 or <0.0001, respectively. 
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6.2 Abbreviations 
 ABC ATP binding cassette 
 ATCC American Type Culture Collection 
 ATP Adenosine triphosphate 
 BCA Bicinchoninic acid 
 BISC BMP-induced signaling complex 
 cDNA Complementary DNA 
 CSCs Cancer stem cells 
 DAPI 4',6-Diamino-2-phenylindole 
 DMEM Dulbecco's Modified Eagle Medium 
 DMSO Dimethylsulfoxide 
 DN Dominant negative 
 DNA Deoxyribonucleic acid 
 dNTP Desoxynukleosid-triphosphate 
 DTT Dithiothreitol 
 DXR Doxorubicin 
 e.g. exempli gratia (for example) 
 EDTA Ethylenediaminetetraacetic acid 
 EMT Epithelial-mesenchymal transition 
 FACS Fluorescence-activated cell sorting 
 FCS Fetal calf serum 
 G Gap 
 M Mitosis 
 MDR Multiple drug resistance 
 MET Mesenchymal to epithelial transition 
 MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
 PAGE Polyacrylamide gel electrophoresis 
 PAH Pulmonary arterial hypertension 
 PBS Phosphate buffered saline 
 PFA Para-formaldehyde 
 PFC Preformed type I-type II heteromeric receptor complex 
 PI Propidium iodide 
 PVDF Polyvinylidene difluoride 
 qPCR Quantitative polymerase chain reaction 
 R Round 
 RNA Ribonucleic acid 
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 ROS Reactive oxygen species 
 RPMI Rosewell park memorial institute 
 RT Reverse transcriptase 
 RTKs Receptor tyrosine kinases 
 S Synthesis 
 SAL Salinomycin 
 SD Standard deviation 
 SDS Sodiumdodecylsulfate 
 SEM Standard error of the mean 
 siRNA Small interfering RNA 
 TAM Tamoxifen 
 TE Trypsin/EDTA 
 TEMED N,N,N′,N′-Tetramethylethan-1,2-diamine 
 UPL Universal probe library 
 WHO World health organization 
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6.3 Genes and Proteins 
 ABC ATP binding cassette 
 ACVR Activin receptor 
 AKT Protein kinase B 
 ALK Activin like kinase 
 BCRP Breast cancer resistance protein 
 BCRP1 Breast cancer resistance protein 
 BMP Bone morphogenetic protein 
 BMP Bone morphogenetic protein 
 BMPR Bone morphogenetic protein receptor 
 BRCA1 Breast cancer 1 
 CDK Cyclin-dependent kinase 
 co-smad Common-mediator Smad 
 EGFR Epidermal growth factor receptor 
 ER Estrogen receptor 
 ERK Extracellular-signal-regulated kinase 
 ERK Extracellular signal-regulated kinases 
 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
 GDF Growth differentiation factor 
 GDF Growth and differentiation factor 
 GST Glutation S-transferase 
 H2AX H2A histone family, member X 
 Her2 Human epidermal growth factor receptor 
 IGF-1R Insulin-like growth factor 1 receptor 
 I-smad Inhibitory Smads 
 JNK C-Jun N-terminal kinases 
 MAPK Mitogen-activated protein kinase 
 MDR1 Multidrug resistance protein 1 
 Oct-4 Octamer-binding transcription factor 4 
 p21 Protein p21 
 p38 MAPK p38 Mitogen-activated protein kinases 
 p53 Protein p53 
 PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
 Rho Ras homologue 
 R-smad Receptor-regulated Smads 
 smad Small  mothers against decapentaplegic 
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SOX-2 SRY (sex determining region Y)-box 2 
 TAB TGF-ß activated binding protein 
 TAK1 TGF-ß activated tyrosine kinase 1 
 TGF-ß Transforming growth factor beta 
 XIAP X-linked inhibitor of apoptosis 
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